National Institute for Health and Care Excellence

Guideline version (Consultation)

Subarachnoid haemorrhage

[F] Evidence review for management of delayed cerebral ischemia

NICE guideline <number> Evidence review underpinning February 2021

Draft for consultation

Developed by the National Guideline Centre, hosted by the Royal College of Physicians



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2020. All rights reserved. Subject to Notice of rights.

<mark>ISBN</mark>

[add for final publication version only, delete this text for consultation version]

Contents

1	Man	ageme	ent of delayed cerebral ischemia (DCI)	5		
	1.1		w question: What is the clinical and cost effectiveness of options for ging delayed cerebral ischaemia?	5		
	1.2					
	1.3	PICO	table	5		
	1.4	Clinical evidence				
		1.4.1	Included studies	6		
		1.4.2	Excluded studies	6		
		1.4.3	Summary of clinical studies included in the evidence review	7		
		1.4.4	Quality assessment of clinical studies included in the evidence review			
	1.5	Econ	omic evidence			
		1.5.1	Included studies	13		
		1.5.2	Excluded studies	13		
		1.5.3	Unit costs	13		
	1.6	Evide	nce statements	13		
		1.6.1	Clinical evidence statements	13		
		1.6.2	Health economic evidence statements	14		
	1.7	The c	ommittee's discussion of the evidence	14		
		1.7.1	Interpreting the evidence	14		
		1.7.2	The quality of the evidence	14		
		1.7.3	Benefits and harms	14		
		1.7.4	Cost effectiveness and resource use	16		
Ар	pendi	ces		27		
	Appe	endix A	: Review protocols	27		
	Appe	endix B	: Literature search strategies	34		
		B.1 C	Clinical search literature search strategy	34		
		B.2 ⊦	lealth Economics literature search strategy	39		
	Appe	endix C	Clinical evidence selection	43		
	Appe	endix D	Clinical evidence tables	44		
	Appe	endix E	: Forest plots	52		
	Appe	endix F	: GRADE tables	55		
	Appe	endix G	: Health economic evidence selection	58		
	Appe	endix H	: Health economic evidence tables	60		
	Appe	endix I:	Excluded studies	61		
		I.1 E	xcluded clinical studies	61		
		I.2 E	xcluded health economic studies	64		

1 1 Management of delayed cerebral ischemia 2 (DCI)

3 Evidence review underpinning recommendation 1.3.7 and research recommendations in the4 NICE guideline.

1.1 5 Review question: What is the clinical and cost

6 effectiveness of options for managing delayed cerebral7 ischaemia?

1.2 8 Introduction

9 Delayed cerebral ischaemia (DCI) is a major cause of poor outcome in people with

- 10 aneurysmal subarachnoid haemorrhage. The pathophysiology of DCI is incompletely
- 11 understood but the condition is characterised by global or focal ischaemic brain injury. Focal
- 12 injury often occurs in the vicinity of the ruptured aneurysm and cerebral angiography may
- 13 show severe arterial narrowing due to vasospasm. Some patients improve with treatment but
- 14 the brain injury can progress to cerebral infarction and death.

15 DCI usually presents 5-10 days after aneurysm rupture with a reduction in consciousness or

- 16 new neurological deficit and the diagnosis is confirmed by exclusion of other causes of
- 17 deterioration (including hypoxia, metabolic disturbance, hypotension, hydrocephalus,
- 18 intracranial bleeding, cerebral oedema). Current practice is to induce hypertension with
- 19 inotropic agents on the presumption that an elevated blood pressure will drive more blood
- 20 through the brain, and so improve ischaemia. Some patients do not respond to medical
- treatment and intra-arterial vasodilators and cerebral artery angioplasty are sometimes usedin these cases.

23 This review assessed the clinical and cost-effectiveness of treatments for delayed cerebral24 ischaemia.

1.325 PICO table

26 For full details see the review protocol in Appendix A:.

27 Table 1: PICO characteristics of review question

Population	Adults (16 and older) with a confirmed delayed cerebral ischemia following a subarachnoid haemorrhage caused by a suspected or confirmed ruptured aneurysm.
Intervention	 Vasopressors (hypertensive treatment) Noradrenaline Metaraminol Inotrope Adrenaline Dobutamine Milrinone Fluid therapy (crystalloid, colloid, albumin) Hypervolemia Euvolemia Intra-arterial vasodilator medication Angioplasty

	Combination of above
Comparison	Comparators: • To each other • Within class • To no treatment
Outcomes	 Critical: Mortality Health and social-related quality of life (any validated measure) Degree of disability or dependence in daily activities, (any validated measure e.g. Modified Rankin Scale and patient-reported outcome measures)
	Important: • Subsequent subarachnoid haemorrhage • Return to usual daily activity e.g. work • Cerebral infarction • Intracranial bleed • Cardiopulmonary complications • Length of stay in hospital
Study design	 Randomised controlled trials (RCTs), systematic reviews of RCTs. If insufficient RCT evidence is available, non-randomised studies will be considered if they adjust for key confounders (age), starting with prospective cohort studies.

1.4 1 Clinical evidence

2 1.4.1 Included studies

- 3 Three studies were included in the review,^{47, 102, 103} these are summarised in Table 2 below.
- 4 These included 1 RCT and 2 retrospective cohort sub-studies of a single RCT. Evidence
- 5 from these studies is summarised in the clinical evidence summary below (Table 3).

6 See also the study selection flow chart in Appendix C: study evidence tables in Appendix D:,7 forest plots in Appendix E: and GRADE tables in Appendix F:.

8 1.4.2 Excluded studies

9 See the excluded studies list in Appendix I:.

1 1.4.3 Summary of clinical studies included in the evidence review

2 Table 2: Summary of studies included in the evidence review

Study Intervention and comparison Population	Outcomes	Comments
Gathier 201847Induced hypertension: Hypertension needed to be started within 3 hours after the start of clinical symptoms of DCI. Hypertension was induced with fluids and norepinephrine over a central venous line placed for this purpose in the intensive care unit (ICU) according to the local protocol of the participating centre. The treatment was continued until improvement of neurological deficits, occurrence of a complication, a maximum MAP of 130 mmHg, or a systolic blood pressure of 230 mmHg. In case of clinical improvement, norepinephrine was continued for at least 48 hours and then slowly tapered. In case of recurrence of symptoms during tapering, norepinephrine was restarted and tapering was attempted 24 hours, norepinephrine was tapered. (n=21)Patients who have had a subarachnoid haemorrhage, above 18 years of age who developed delayed cerebral ischemiaGathier 201847Induced with fluids and norepinephrine was restarted and tapering was attempted 24 hours, norepinephrine was tapered. (n=21)Patients who have had a subarachnoid haemorrhage, above 18 years of age who developed delayed cerebral ischemiaDescriptionIn case of recurrence of symptoms during tapering, norepinephrine was tapered. (n=21)Patients who have had a subarachnoid haemorrhage, above 18 years of age who developed delayed cerebral ischemiaInduced with fluids and norepinephrine was tapered. (n=21)Patients who have had a subarachnoid haemorrhage, above 18 years of age who developed delayed cerebral ischemiaInduced with fluids and norepinephrine was tapered. (n=21)Patients who have had a subarachnoid haemorrhage, Above 18 years of age who developed delayed cerebral	 Degree of disability (mRS at 3 months) Activity of daily living (Barthel Index) Quality of life (stroke specific quality of life scale) Anxiety and Depression (Hospital anxiety and depression scale) 	Trial stopped prematurely due to difficulties with participant recruitment and lack of clinical efficacy

Study	Intervention and comparison	Population	Outcomes	Comments
	In the no hypertension group, hypertension was not induced, but a minimal MAP of 80 mmHg was maintained with fluids and, when necessary, with vasopressors. In the latter case, a central venous line was placed, but otherwise, no central venous lines were used in the no hypertension group (n=20) All patients were treated with oral nimodipine and fluid administration aimed at normovolemia. Follow-up: 3 months			
Polin 1998 ¹⁰³	Intra-arterial vasodilator medication (papaverine): Patients were treated with intra- arterial infusions of 0.09% (90mg in 100ml) up to a higher dose of 0.8% (800mg in 100ml) papaverine for each vascular territory (n=31) Control: Patients were matched to the papaverine cohort by gender, same dose of study drug (tirilazad), age within 10 years and degree of arterial narrowing (n=62)	Patients who have been treated for subarachnoid haemorrhage that have symptomatic vasospasm Mean age: 56.7 years (range 40-70) USA Retrospective cohort study	 Degree of disability (mRS ≤2) 	Study is a subgroup analysis from the North American Tirilizad trial of 54 medical centres, of patients with subarachnoid haemorrhage. Participants were matched with patients from the same trial who exhibited similar clinical characteristics (including age, degree of vasospasm and the GCS scores) but received medical management alone for vasospasm.

Study	Intervention and comparison	Population	Outcomes	Comments
	Trial protocol: As part of the main clinical trial, 14 patients had received placebo (vehicle), 6 received 2mg/kg/day Tirilizad and 11 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given. Follow-up: 3 months			
Polin 2000 ¹⁰²	Angioplasty: Group consisted of patients who had been treated with Angioplasty alone or Angioplasty plus papaverine if symptomatic of cerebral vasospasm (n=38) Control: Patients were matched to the Angioplasty cohort by gender, same dose of study drug, age within 10 years and degree of arterial narrowing (n=83) Trial protocol: As part of the main clinical trial, 14 patients had received placebo (vehicle), 6 received 2mg/kg/day Tirilizad and 11 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given.	Patients who have been treated for subarachnoid haemorrhage that have symptomatic vasospasm Mean age: 48.1 years (range 30-77) USA Retrospective cohort study	 Degree of disability (mRS ≤2) 	Study is a subgroup analysis from the North American Tirilizad trial of 54 medical centres, of patients with subarachnoid haemorrhage. A conditional logistic regression analysis was performed in which patients were compared with individuals matched for age, sex, dose of study drug, admission neurological grade, and GCS score at the time of angioplasty.

	Study	Intervention and comparison	Population	Outcomes	Comments		
		Follow-up: 3 months					
1 :	1 See Appendix D: for full evidence tables.						
2	2						
3 '	3 1.4.4 Quality assessment of clinical studies included in the evidence review						

4 Table 3: Clinical evidence summary: Intra-arterial vasodilator medication (Papaverine) versus control (no papaverine)

•		ounnury: maa u		ii (i upuvoiiiio)	101000 001111		
		No of			Anticipated absolute effects		
	Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Papaverine (95% CI)	
	Degree of disability (mRS	93	$\oplus \ominus \ominus \ominus$	RR 0.78	Moderate		
	≤2) scale 0-6; high score represents poor outcome	e 0-6; high score 3 months due to risk of bias, imprecision		(0.5 to 1.21)	581 per 1000	128 fewer per 1000 (from 290 fewer to 122 more)	

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

5 Table 4: Clinical evidence summary: Angioplasty versus control (no angioplasty)

	No of			Anticipated absolute effects		
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Angioplasty (95% Cl)	
Degree of disability (mRS	121	$\oplus \Theta \Theta \Theta$	RR 0.92	Moderate		
≤2) scale 0-6; high score represents poor outcome	(1 study) 3 months	VERY LOW1,2 due to risk of bias, imprecision	(0.66 to 1.28)	602 per 1000	48 fewer per 1000 (from 205 fewer to 169 more)	

	No of			Anticipated absolute effects	
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Angioplasty (95% CI)

1 Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

1 Table 5: Clinical evidence summary: Norepinephrine + Fluids (Hypertension) versus control (no induced hypertension)

	No of			Anticipated absolute effects		
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Norepinephrine + Fluids (95% CI)	
mRS 0 – no symptoms	41	$\oplus \oplus \ominus \ominus$	Peto OR 0.12	Moderate		
	(1 study) 3 months	LOW1 due to imprecision	(0.01 to 2.02)	100 per 1000	81 fewer per 1000 (from 99 fewer to 275 more)	
mRS 1 – no significant	41	$\oplus \oplus \ominus \ominus$	RR 0.24	Moderate		
disability	(1 study) 3 months	LOW1 due to imprecision	(0.03 to 1.95)	200 per 1000	152 fewer per 1000 (from 194 fewer to 190 more)	
mRS 2 – slight	41 (1 study) 3 months	⊕⊕⊖⊖ LOW1 due to imprecision	RR 1.9 (0.55 to 6.6)	Moderate		
disability				150 per 1000	135 more per 1000 (from 68 fewer to 840 more)	
mRS 3 – moderate	41	$\oplus \oplus \ominus \ominus$	RR 0.63	Moderate		
disability	(1 study) 3 months	LOW1 due to imprecision	(0.12 to 3.41)	150 per 1000	56 fewer per 1000 (from 132 fewer to 362 more)	
mRS 4 –	41	$\oplus \oplus \ominus \ominus$	RR 0.95	Moderate		
moderate/severe disability	(1 study) 3 months	LOW1 due to imprecision	(0.22 to 4.18)	150 per 1000	8 fewer per 1000 (from 117 fewer to 477 more)	
mRS 5- severe	41	$\oplus \oplus \ominus \ominus$	RR 2.86	Moderate		
disability	(1 study) 3 months	LOW1 due to imprecision	(0.32 to 25.24)	50 per 1000	93 more per 1000 (from 34 fewer to 1000 more)	
mRS 6 - dead				Moderate		

	No of			Anticipated absolute effects	
Outcomes	Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Risk with Control	Risk difference with Norepinephrine + Fluids (95% CI)
	41 (1 study) 3 months	⊕⊕⊝⊝ LOW1 due to imprecision	RR 1.43 (0.47 to 4.32)	200 per 1000	86 more per 1000 (from 106 fewer to 664 more)

1 Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

2 Table 6: Evidence not suitable for GRADE: Norepinephrine + Fluids (Hypertension) versus control

Outcome	Study (no. of participants)	Risk of bias	Comparison results (Median, IQR)	Intervention results	<i>P</i> value
Activities of Daily Living (Barthel Index) Scale 0 – 20	Gathier 2018 n=41	Low	Normotension: 20 (16-20)	Hypertension: 20 (10-20)	-
Quality of Life (Stroke specific quality of life scale)	Gathier 2018 n=41	Low	Normotension: 49 (35-55)	Hypertension: 47 (35-55)	-
Anxiety & Depression (Hospital Anxiety & Depression scales) Scale 0 – 21 (each)	Gathier 2018 n=41	Low	Normotension: 8 (4-11)	Hypertension: 13 (3-13)	-

3 Data reported as median value and IQR and so was not suitable for inclusion in GRADE analysis

4 See Appendix F: for full GRADE tables.

5

1

1.5 1 Economic evidence

2 1.5.1 Included studies

3 No health economic studies were included.

4 1.5.2 Excluded studies

- 5 No relevant health economic studies were excluded due to assessment of limited6 applicability or methodological limitations.
- 7 See also the health economic study selection flow chart in Appendix G:.

8 1.5.3 Unit costs

9 Relevant unit costs are provided below to aid consideration of cost effectiveness.

10 Table 7: UK costs of treatments for angioplasty

Procedure	Description	Average cost
Angioplasty	Percutaneous Transluminal Angioplasty, including stenting, of Intracranial or Extracranial Blood Vessel [NHS Reference Cost code YA10Z]	£4,390
Placement of central venous catheter	(Peripheral) Insertion of (Non-Tunnelled or Tunnelled) Central Venous Catheter, 19 years and over [weighted average of NHS Reference Cost codes YR40A, YR41A, YR42A]	£1,239

11 Source: NHS Reference Costs 2018/1996

12 Table 8: UK costs of norepinepherine

Drug	Cost/unit (£)
Noradrenaline (2mg/2ml) solution	£ 2.40
Noradrenaline (4mg/4ml) concentrate for solution	£ 5.80
Noradrenaline (4mg/4ml) solution	£ 4.40
Noradrenaline (8mg/8ml) concentrate for solution	£ 11.60

13 Source: British National Formulary, August 2020⁶⁵

14 Table 9: UK costs of drugs for fluid management

Prenaration	Dose	Cost per unit
•		£13.50 - £67.50
Infusion	200ml	£75.00
Infusion	6% 500ml	£10.63 - £15.30
		Infusion50mg per 1mlInfusion200ml

¹⁵ Source: British National Formulary, August 202065

1.6₁₆ Evidence statements

17 1.6.1 Clinical evidence statements

18 Three outcome measures for health related quality of life from 1 study were not suitable for 19 inclusion in the GRADE summary tables.

- 1 The study found no significant difference between people receiving norepinephrine and fluids
- 2 (hypertension) or no treatment (normotension) in activities of daily living, quality of life, or
- 3 anxiety and depression. (n=41, low risk of bias).

4 **1.6.2** Health economic evidence statements

5 No relevant economic evaluations were identified.

1.7 6 The committee's discussion of the evidence

7 1.7.1 Interpreting the evidence

1.7.1.1 8 The outcomes that matter most

9 The critical outcomes for this review were mortality; health and social-related quality of life

- 10 (any validated measure); and degree of disability or dependence in daily activities (any
- 11 validated measure e.g. Modified Rankin Scale and patient-reported outcome measures). The
- 12 committee also considered subsequent subarachnoid haemorrhage; return to usual daily
- 13 activity e.g. work; cerebral infarction; intracranial bleed; cardiopulmonary complications; and
- 14 length of stay in hospital to be important outcomes.
- 15 Evidence was identified for degree of disability or dependence in daily activities. No evidence
- 16 was found for the remaining outcomes.

17 1.7.2 The quality of the evidence

18 The evidence in this review included data from 1 RCT and 2 retrospective cohort sub-studies 19 of a single RCT. The 2 observational studies compared the intervention groups with matched 20 control groups to account for key confounders, including age.

The evidence ranged from low to very low quality, with the majority of the evidence of low quality due to the risk of bias and imprecision. The committee noted a risk of selection bias and a lack of blinding in treatment provision and outcome assessment. There was a high level of uncertainty due to significant statistical imprecision for most outcomes. Imprecision was indicated by wide confidence intervals crossing the thresholds for clinical significance, with which the committee would typically judge if an intervention shows benefit or harm. This reflected the small size of the studies and the low event rate of some outcomes. The committee agreed that a clinical recommendation could not be based on the evidence available due to its insufficient quality and quantity. Instead, the committee agreed a consensus recommendation based on their own clinical experience and understanding, recommending the use of vasopressor therapy to raise blood pressure in euvolaemic patients with delayed cerebral ischaemia.

33 1.7.3 Benefits and harms

The committee highlighted that delayed cerebral ischaemia is a serious complication of aSAH and is associated with significant morbidity and mortality. Delayed cerebral ischaemia can cause catastrophic deterioration in a patient who has previously been stable, and an effective treatment could have significant benefit.

38 The committee agreed that patients with suspected delayed cerebral ischaemia should be

39 assessed clinically and investigated with CT brain imaging to exclude other causes of

40 neurological deterioration. Treatments to target DCI can be started once it is determined that

41 DCI is the most likely cause of neurological deterioration.

42 Norepinephrine + fluids vs Control (no induced hypertension):

One randomised controlled trial assessed norepinephrine and intravenous fluids compared to routine fluid management in people with delayed cerebral ischaemia. Norepinephrine (a vasopressor) and intravenous fluid were used to increase blood pressure with the objective of improving cerebral blood flow to limit or prevent cerebral infarction. Administration of norepinephrine and fluids was not associated with lower disability (mRS) at 3 months. There were significantly fewer participants with the lowest level of disability (mRS 0 or 1) with intervention, although there were significantly more people with an mRS of 2 (slight levels of disability) and mRS 5 (severe disability) with intervention. There was no clinically important difference between groups for those with mRS of 3 or 4. The committee noted that there was a clinically significant increase in mortality rate in the norepinephrine and fluids group compared to routine fluid management, although the evidence was of low quality with very serious imprecision around the point estimate. The committee agreed that the quantity and quality of evidence on norepinephrine was insufficient to support a recommendation.

14 The committee recognised that the use of norepinephrine to increase blood pressure is 15 established practice for people with a clinical diagnosis of delayed cerebral ischaemia and 16 may result in acute improvement in the patient's condition. The committee agreed that the 17 historical practice of maintaining hypervolaemia (an artificially high blood volume) can result 18 in adverse events such as pulmonary oedema, dilutional hyponatremia, coagulopathy, and 19 aneurysm rebleeding. In current practice most clinicians therefore administer intravenous 20 fluid to ensure euvolaemia and if symptoms persist a vasopressor (such as norepinephrine) 21 is administered to raise systemic blood pressure. The committee acknowledged that many 22 patients benefit in the short-term from these measures but there is no evidence of impact on 23 longer-term outcome. Nevertheless, the committee agreed a consensus recommendation 24 that people with delayed cerebral ischaemia after an aneurysmal subarachnoid haemorrhage 25 should be given intravenous fluid to ensure euvolaemia (normal blood volume) and treatment 26 with a vasopressor should be considered if symptoms persist, accepting that clinical 27 improvement with a vasopressor may be temporary. The committee also agreed to make a 28 research recommendation on the role of vasopressors in people with delayed cerebral 29 ischaemia.

30 The management of patients who do not improve with a vasopressor varies widely but some

31 clinicians recommend cerebral angiography and intra-arterial therapies, including intra-

32 arterial vasodilators and angioplasty.

33 Angioplasty vs Control (no angioplasty):

34 One small retrospective cohort study compared intra-cranial arterial angioplasty with no 35 intervention in patients with delayed cerebral ischaemia. Angioplasty showed no clinically 36 important difference in the degree of disability, as measured by the number of patients with a 37 favourable outcome (mRS \leq 2). The committee agreed that the evidence on angioplasty was 38 insufficient to support a recommendation.

From their experience the committee were aware that use of angioplasty varies widely in current practice and although the procedure can lead to immediate clinical improvement in some patients, it is associated with procedural risks including stroke, bleeding from arterial access sites, and complications of anaesthesia. The committee were not able to reach a consensus on the use of angioplasty and concluded that further research reviewing the efficacy of intra-arterial therapies is required.

45 Intra-arterial vasodilator medication (Papaverine) versus control (no papaverine):

46 Evidence from 1 retrospective cohort study showed that fewer patients achieved a favourable

47 outcome (mRS \leq 2 at follow-up) with intra-arterial papaverine compared to a control group.

48 This difference was deemed to be clinically significant. The committee also noted that

49 papaverine is not commonly used in current practice. The committee agreed that the

50 evidence on papaverine was insufficient to support a recommendation.

1 The committee made a research recommendation on the role of intra-arterial therapies in the 2 management of patients with delayed cerebral ischaemia.

3 The committee noted the evidence available on the clinical and cost effectiveness of

4 interventions to manage DCI in people who have experienced an aSAH, was of insufficient

5 quality and quantity to inform any recommendations. The committee therefore referred to

6 their clinical experience to form a consensus recommendation. The committee agreed that in

7 people with a clinical diagnosis of delayed cerebral ischaemia, treatment with vasopressors

8 along with close monitoring is established practice and could be considered once euvolemia

9 is ensured. The committee highlighted that short-term clinical improvement with10 vasopressors may not translate into better longer-term clinical outcomes.

11 **1.7.4 Cost effectiveness and resource use**

12 No published economic evaluations were identified for this review. Unit costs were presented 13 to the committee for consideration of cost effectiveness.

14 With the aid of unit costs the committee made a consensus recommendation for a

15 vasopressor in euvolaemic people with delayed cerebral ischaemia. The recommendation is

16 not expected to have a substantial resource impact as it is reflective of current practice in

17 England.

1 References

- Aburto-Murrieta Y, Marquez-Romero JM, Bonifacio-Delgadillo D, Lopez I, Hernandez-Curiel B. Endovascular treatment: balloon angioplasty versus nimodipine intra-arterial for medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Vascular and Endovascular Surgery. 2012; 46(6):460-465
- 6 2. Adami D, Berkefeld J, Platz J, Konczalla J, Pfeilschifter W, Weidauer S et al.
 7 Complication rate of intraarterial treatment of severe cerebral vasospasm after
 8 subarachnoid hemorrhage with nimodipine and percutaneous transluminal balloon
 9 angioplasty: worth the risk? Journal of Neuroradiology. 2019; 46(1):15-24
- Ades PE, Desbordes JM, Guggiari M. Use of intravenous nimodipine in the curative treatment of cerebral vasospasm secondary to subarachnoid haemorrhage following ruptures aneurysm. Annales Françaises d'Anesthésie et de Réanimation. 1987; 6(Suppl 1):R146
- Akdemir H, Kulakszoglu EO, Tucer B, Menku A, Postalc L, Gunald O. Magnesium
 sulfate therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
 Neurosurgery Quarterly. 2009; 19(1):35-39
- Allen GS. Role of calcium antagonists in cerebral arterial spasm. American Journal of
 Cardiology. 1985; 55(3):B149-B153
- Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN et al. Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage.
 New England Journal of Medicine. 1983; 308(11):619-624
- Andaluz N, Tomsick TA, Tew JM, Jr., van Loveren HR, Yeh HS, Zuccarello M.
 Indications for endovascular therapy for refractory vasospasm after aneurysmal
 subarachnoid hemorrhage: experience at the University of Cincinnati. Surgical
 Neurology. 2002; 58(2):131-138; discussion 138
- Arakawa Y, Kikuta K, Hojo M, Goto Y, Yamagata S, Nozaki K et al. Milrinone reduces
 cerebral vasospasm after subarachnoid hemorrhage of WFNS grade IV or V.
 Neurologia Medico-Chirurgica. 2004; 44(8):393-400; discussion 401
- Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS et al.
 Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. American Journal of Neuroradiology. 2004; 25(5):819-826
- Barbarawi M, Smith SF, Jamous MA, Haboub H, Suhair Q, Abdullah S. Therapeutic
 approaches to cerebral vasospasm complicating ruptured aneurysm. Neurology
 International. 2009; 1(1):e13
- Bashir A, Andresen M, Bartek J, Jr., Cortsen M, Eskesen V, Wagner A. Intra-arterial
 nimodipine for cerebral vasospasm after subarachnoid haemorrhage: influence on
 clinical course and predictors of clinical outcome. Neuroradiology Journal. 2016;
 29(1):72-81
- Biondi A, Ricciardi GK, Puybasset L, Abdennour L, Longo M, Chiras J et al. Intraarterial nimodipine for the treatment of symptomatic cerebral vasospasm after
 aneurysmal subarachnoid hemorrhage: preliminary results. American Journal of
 Neuroradiology. 2004; 25(6):1067-1076
- 43 13. Boet R, Chan MT, Poon WS, Wong GK, Wong HT, Gin T. Intravenous magnesium
 sulfate to improve outcome after aneurysmal subarachnoid hemorrhage: interim
 report from a pilot study. Acta Neurochirurgica Supplementum. 2005; 95:263-264

1 2 3	14.	Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000; 47(3):602-606; discussion 606-607
4 5 6 7	15.	Boulouis G, Labeyrie MA, Raymond J, Rodriguez-Regent C, Lukaszewicz AC, Bresson D et al. Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis. European Radiology. 2017; 27(8):3333-3342
8 9 10	16.	Bradford CM, Finfer S, O'Connor A, Yarad E, Firth R, McCallister R et al. A randomised controlled trial of induced hypermagnesaemia following aneurysmal subarachnoid haemorrhage. Critical Care and Resuscitation. 2013; 15(2):119-125
11 12 13 14	17.	Brandt L, Ljunggren B, Saveland H, Andersson KE, Vinge E. Cerebral vasospasm and calcium channel blockade. Nimodipine treatment in patients with aneurysmal subarachnoid hemorrhage. Acta Pharmacologica et Toxicologica. 1986; 58 (Suppl 2):151-155
15 16 17	18.	Brathwaite S, Macdonald RL. Current management of delayed cerebral ischemia: update from results of recent clinical trials. Translational Stroke Research. 2014; 5(2):207-226
18 19 20	19.	Brewer RP, Parra A, Lynch J, Chilukuri V, Borel CO. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. Journal of Neurosurgical Anesthesiology. 2001; 13(3):202-206
21 22	20.	Buchheit F, Boyer P. Review of treatment of symptomatic cerebral vasospasm with nimodipine. Acta Neurochirurgica - Supplementum. 1988; 45:51-55
23 24 25 26	21.	Chalouhi N, Tjoumakaris S, Thakkar V, Theofanis T, Hammer C, Hasan D et al. Endovascular management of cerebral vasospasm following aneurysm rupture: outcomes and predictors in 116 patients. Clinical Neurology and Neurosurgery. 2014; 118:26-31
27 28 29 30	22.	Chaudhry NS, Orning JL, Shakur SF, Amin-Hanjani S, Aletich VA, Charbel FT et al. Safety and efficacy of balloon angioplasty of the anterior cerebral artery for vasospasm treatment after subarachnoid hemorrhage. Interventional Neuroradiology. 2017; 23(4):372-377
31 32 33	23.	Chen PR, Bulsara K, Lopez-Rivera V, Sheriff FG, Sanzgiri A, Sheth S et al. Use of single versus multiple vasodilator agents in the treatment of cerebral vasospasm: is more better than less? Acta Neurochirurgica. 2020; Epublication
34 35 36	24.	Chen T, Carter BS. Role of magnesium sulfate in aneurysmal subarachnoid hemorrhage management: a meta-analysis of controlled clinical trials. Asian Journal of Neurosurgery. 2011; 6(1):26-31
37 38 39	25.	Cho WS, Kang HS, Kim JE, Kwon OK, Oh CW, Son YJ et al. Intra-arterial nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Interventional Neuroradiology. 2011; 17(2):169-178
40 41 42 43	26.	Choi BJ, Lee TH, Lee JI, Ko JK, Park HS, Choi CH. Safety and efficacy of transluminal balloon angioplasty using a compliant balloon for severe cerebral vasospasm after an aneurysmal subarachnoid hemorrhage. Journal of Korean Neurosurgical Society. 2011; 49(3):157-162
44 45 46	27.	Coyne TJ, Montanera WJ, Macdonald RL, Wallace MC. Percutaneous transluminal angioplasty for cerebral vasospasm after subarachnoid hemorrhage. Canadian Journal of Surgery. 1994; 37(5):391-396

28. Crespy T, Heintzelmann M, Chiron C, Vinclair M, Tahon F, Francony G et al. Which 1 2 protocol for milrinone to treat cerebral vasospasm associated with subarachnoid 3 hemorrhage?S. Journal of Neurosurgical Anesthesiology. 2019; 31(3):323-329 4 29. Curran MP, Robinson DM, Keating GM. Intravenous nicardipine: its use in the short-5 term treatment of hypertension and various other indications. Drugs. 2006; 6 66(13):1755-1782 7 30. Dehdashti AR, Binaghi S, Uske A, Regli L. Intraarterial nimodipine for the treatment of 8 symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a preliminary 9 study. Neurology India. 2011; 59(6):810-816 10 31. Desbordes JM, Ades PE, Guggiari M. Intravenous nimodipine in the treatment of 11 cerebral vasospasm following subarachnoid hemorrhage caused by aneurysm 12 rupture: a comparative multicenter study. Agressologie. 1989; 30(7):438-440 13 32. Duman E, Karakoc F, Pinar HU, Dogan R, Firat A, Yildirim E. Higher dose intra-14 arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a 15 rescue therapy for refractory cerebral vasospasm. Interventional Neuroradiology. 16 2017; 23(6):636-643 17 33. Ehlert A, Schmidt C, Wolfer J, Manthei G, Jacobs AH, Bruning R et al. Molsidomine 18 for the prevention of vasospasm-related delayed ischemic neurological deficits and 19 delayed brain infarction and the improvement of clinical outcome after subarachnoid 20 hemorrhage: a single-center clinical observational study. Journal of Neurosurgery. 21 2016; 124(1):51-58 22 34. Etminan N, Macdonald RL, Davis C, Burton K, Steiger HJ, Hanggi D. Intrathecal 23 application of the nimodipine slow-release microparticle system eg-1962 for 24 prevention of delayed cerebral ischemia and improvement of outcome after 25 aneurysmal subarachnoid hemorrhage. Acta Neurochirurgica - Supplement. 2015; 26 120:281-286 27 35. Feigin VL, Rinkel GJ, Algra A, van Gijn J. Circulatory volume expansion for aneurysmal subarachnoid hemorrhage. Cochrane Database of Systematic Reviews 28 29 2004, Issue 4. Art. No.: CD000483. DOI: 10.1002/14651858.CD000483.pub2. 30 36. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J. Calcium antagonists in 31 patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology. 32 1998; 50(4):876-883 33 37. Feng L, Fitzsimmons BF, Young WL, Berman MF, Lin E, Aagaard BD et al. 34 Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: 35 safety and 2-year experience. American Journal of Neuroradiology. 2002; 23(8):1284-36 1290 37 38. Firlik AD, Kaufmann AM, Jungreis CA, Yonas H. Effect of transluminal angioplasty on 38 cerebral blood flow in the management of symptomatic vasospasm following 39 aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 1997; 86(5):830-40 839 41 39. Fountas KN, Machinis TG, Robinson JS, Sevin C, Fezoulidis NI, Castresana M et al. 42 The role of magnesium sulfate in the treatment of vasospasm in patients with 43 spontaneous subarachnoid haemorrhage. 'In:' Kırış T, Zhang JH, editors. Cerebral 44 Vasospasm Acta Neurochirurgica Supplementum. 104. Vienna: Springer. 2008. p. 269-273. 45 46 40. Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after 47 subarachnoid hemorrhage. Critical Care. 2016; 20(1):277

1 41. Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the 2 treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. 3 Stroke. 2008; 39(3):893-898 4 42. Friedlich D, Agner C, Boulos AS, Mesfin F, Feustel P, Bernardini GL et al. 5 Retrospective analysis of parenteral magnesium sulfate administration in decreased 6 incidence of clinical and neuroradiological cerebral vasospasm: a single center 7 experience. Neurological Research. 2009; 31(6):621-625 8 43. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N et al. 9 Clinical response to hypertensive hypervolemic therapy and outcome after 10 subarachnoid hemorrhage. Neurosurgery. 2010; 66(1):35-41; discussion 41 11 44. Frontera JA, Gowda A, Grilo C, Gordon E, Johnson D, Winn HR et al. Recurrent vasospasm after endovascular treatment in subarachnoid hemorrhage. Acta 12 13 Neurochirurgica - Supplement. 2011; 110(Pt 2):117-122 14 45. Gathier C, Van den Bergh W, Van der Jagt M, Verweij B, Dankbaar JW, Muller M. Complications and clinical outcome after induced hypertension as treatment for 15 16 delayed cerebral ischaemia in aneurysmal subarachnoid haemorrhage: a randomised clinical trial. European Stroke Journal. 2017; 2(Suppl 1):143 17 18 46. Gathier CS, van den Bergh WM, Slooter AJ, Group HI-S. HIMALAIA (Hypertension 19 Induction in the Management of AneurysmaL subArachnoid haemorrhage with secondary IschaemiA): a randomized single-blind controlled trial of induced 20 21 hypertension vs. no induced hypertension in the treatment of delayed cerebral 22 ischemia after subarachnoid hemorrhage. International Journal of Stroke. 2014; 23 9(3):375-380 24 47. Gathier CS, van den Bergh WM, van der Jagt M, Verweij BH, Dankbaar JW, Müller 25 MC et al. Induced hypertension for delayed cerebral ischemia after aneurysmal 26 subarachnoid hemorrhage: A randomized clinical trial. Stroke. 2018; 49(1):76-83 27 48. Goel R, Aggarwal A, Salunke P, Kumar A, Chhabra R. Is intra arterial nimodipine 28 really beneficial in vasospasm following aneurysmal subarachnoid haemorrhage? 29 British Journal of Neurosurgery. 2016; 30(4):407-410 30 49. Goodson K, Lapointe M, Monroe T, Chalela JA. Intraventricular nicardipine for 31 refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocritical Care. 32 2008; 8(2):247-252 33 50. Gross BA, Tonetti DA, Weiner GM, Panczykowski DM, Ares WJ, Kenmuir CL et al. Septoplasty: scepter balloon angioplasty for vasospasm after aneurysmal 34 35 subarachnoid hemorrhage. Interventional Neurology. 2017; 6(3-4):229-235 36 51. Guggiari M, Taquoi G, Philippon J, Viars P. Curative treatment with intravenous 37 nimodipine for cerebral vasospasm after subarachnoid haemorrhage due to aneurism 38 rupture. Anesthesiology. 1987; 67(3A):A584 39 52. Haegens NM, Gathier CS, Horn J, Coert BA, Verbaan D, van den Bergh WM. 40 Induced hypertension in preventing cerebral infarction in delayed cerebral ischemia 41 after subarachnoid hemorrhage. Stroke. 2018; 49(11):2630-2636 42 53. Hafeez S, Grandhi R. Systematic review of intrathecal nicardipine for the treatment of 43 cerebral vasospasm in aneurysmal subarachnoid hemorrhage. Neurocritical Care. 44 2019; 31:399-405 45 54. Hanggi D, Beseoglu K, Turowski B, Steiger HJ. Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and 46 47 endovascular therapy. Clinical Neurology and Neurosurgery. 2008; 110(8):784-790

1 55. Harada K, Ihara K, Ikeda N, Iwamoto N, Ueda Y, Furutani Y. The preventive effect of 2 nifedipine on cerebral vasospasms after an aneurysmal subarachnoid hemorrhage: a 3 clinical study. Japanese Journal of Neurosurgery. 1995; 4(3):263-269 4 56. Hasegawa S, Hasegawa Y, Miura M. Current therapeutic drugs against cerebral 5 vasospasm after subarachnoid hemorrhage: a comprehensive review of basic and 6 clinical studies Current Drug Delivery. 2016; 14(6):843-852 7 57. Hockel K, Diedler J, Steiner J, Birkenhauer U, Danz S, Ernemann U et al. Long-term, 8 continuous intra-arterial nimodipine treatment of severe vasospasm after aneurysmal 9 subarachnoid hemorrhage. World Neurosurgery. 2016; 88:104-112 10 58. Hongo K, Kobayashi S. Calcium antagonists for the treatment of vasospasm following 11 subarachnoid haemorrhage. Neurological Research. 1993; 15(4):218-224 Hosmann A, Rauscher S, Wang WT, Dodier P, Bavinzski G, Knosp E et al. Intra-12 59. 13 arterial papaverine-hydrochloride and transluminal balloon angioplasty for 14 neurointerventional management of delayed-onset post-aneurysmal subarachnoid 15 hemorrhage vasospasm. World Neurosurgery. 2018; 119:e301-e312 16 60. Huang B, Khatibi NH, Tong L, Yan P, Xie P, Zhang JH. Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study. 17 18 Translational Stroke Research. 2010; 1(2):108-112 19 61. Hui C, Lau KP. Efficacy of intra-arterial nimodipine in the treatment of cerebral 20 vasospasm complicating subarachnoid haemorrhage. Clinical Radiology. 2005; 21 60(9):1030-1036 22 62. Iwabuchi S, Yokouchi T, Hayashi M, Sato K, Saito N, Hirata Y et al. Intra-arterial 23 administration of fasudil hydrochloride for vasospasm following subarachnoid 24 haemorrhage: experience of 90 cases. Acta Neurochirurgica - Supplement. 2011; 25 110(Pt 2):179-181 26 63. Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in 27 patients with established cerebral vasospasm after rupture of intracranial aneurysms. 28 Neurosurgery. 1988; 23(2):154-157 29 64. Jestaedt L, Pham M, Bartsch AJ, Kunze E, Roosen K, Solymosi L et al. The impact of 30 balloon angioplasty on the evolution of vasospasm-related infarction after aneurysmal 31 subarachnoid hemorrhage. Neurosurgery. 2008; 62(3):610-617; discussion 610-617 32 65. Joint Formulary Committee. British National Formulary (BNF) (August 2020) update. 33 Available from: http://www.bnf.org.uk Last accessed: 05/08/2020. 34 66. Jun P, Hetts S, Tatum JK, Dowd CF, Ko NU. Outcomes from cerebral vasospasm following subarachnoid hemorrhage at a tertiary care center. Stroke. 2010; 35 36 41(4):e236 37 67. Kasuya H. Clinical trial of nicardipine prolonged-release implants for preventing 38 cerebral vasospasm: multicenter cooperative study in Tokyo. Acta Neurochirurgica -39 Supplement. 2011; 110(Pt 2):165-167 Katoh H, Shima K, Shimizu A, Takiguchi H, Miyazawa T, Umezawa H et al. Clinical 40 68. 41 evaluation of the effect of percutaneous transluminal angioplasty and intra-arterial 42 papaverine infusion for the treatment of vasospasm following aneurysmal 43 subarachnoid hemorrhage. Neurological Research. 1999; 21(2):195-203 44 69. Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R. A case control study of statin 45 and magnesium administration in patients after aneurysmal subarachnoid

- hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurological
 Research. 2008; 30(9):893-897
- Khatri R, Memon MZ, Zacharatos H, Taqui AM, Qureshi MH, Vazquez G et al. Impact
 of percutaneous transluminal angioplasty for treatment of cerebral vasospasm on
 subarachnoid hemorrhage patient outcomes. Neurocritical Care. 2011; 15(1):28-33
- 6 71. Khatri R, Tariq N, Vazquez G, Suri MF, Ezzeddine MA, Qureshi AI. Outcomes after
 7 nontraumatic subarachnoid hemorrhage at hospitals offering angioplasty for cerebral
 8 vasospasm: a national level analysis in the United States. Neurocritical Care. 2011;
 9 15(1):34-41
- 10 72. Kim JH, Park IS, Park KB, Kang DH, Hwang SH. Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Journal of Korean Neurosurgical Society. 2009; 46(3):239-244
- 13 73. Kimball MM, Velat GJ, Hoh BL, Participants in the International Multi-Disciplinary
 Consensus Conference on the Critical Care Management of Subarachnoid H. Critical
 care guidelines on the endovascular management of cerebral vasospasm.
 Neurocritical Care. 2011; 15(2):336-341
- 17 74. Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. Journal of Cardiovascular Pharmacology. 2005; 45(2):182-191
- 19 75. Kiser T. Pharmacologic options for prevention and management of cerebral
 20 vasospasm in aneurysmal subarachnoid hemorrhage. Hospital Pharmacy. 2013;
 21 48(Suppl. 5):S2-S9
- Koos WT, Perneczky A, Auer LM, Boker DK, Gaab M, Jaksche H et al. Nimodipine
 treatment of ischemic neurological deficits due to cerebral vasospasm after
 subarachnoid hemorrhage. Clinical results of a multicenter study. Neurochirurgia.
 1985; 28(Suppl 1):114-117
- 26 77. Koyanagi M, Fukuda H, Lo B, Uezato M, Kurosaki Y, Sadamasa N et al. Effect of
 27 intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after
 28 aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 2018; 128(3):71729 722
- 30 78. Lannes M, Teitelbaum J, del Pilar Cortes M, Cardoso M, Angle M. Milrinone and
 homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage:
 the Montreal Neurological Hospital protocol. Neurocritical Care. 2012; 16(3):354-362
- 33 79. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H et al. Effect of
 hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a
 randomized controlled trial. Stroke. 2000; 31(2):383-391
- 36 80. Levati A, Solaini C, Boselli L. Prevention and treatment of vasospasm. Journal of
 37 Neurosurgical Sciences. 1998; 42(1 Suppl 1):27-31
- Li Y, Fang W, Tao L, Li M, Yang Y, Gao Y et al. Efficacy and safety of intravenous
 nimodipine administration for treatment of hypertension in patients with intracerebral
 hemorrhage. Neuropsychiatric Disease and Treatment. 2015; 11:1231-1238
- 41 82. Liu-Deryke X, Rhoney DH. Cerebral vasospasm after aneurysmal subarachnoid
 42 hemorrhage: an overview of pharmacologic management. Pharmacotherapy. 2006;
 43 26(2):182-203
- 44 83. Liu JK, Tenner MS, Gottfried ON, Stevens EA, Rosenow JM, Madan N et al. Efficacy
 of multiple intraarterial papaverine infusions for improvement in cerebral circulation

1 time in patients with recurrent cerebral vasospasm. Journal of Neurosurgery. 2004; 2 100(3):414-421 3 84. Loan JJM, Wiggins AN, Brennan PM. Medically induced hypertension, hypervolaemia 4 and haemodilution for the treatment and prophylaxis of vasospasm following 5 aneurysmal subarachnoid haemorrhage: systematic review. British Journal of 6 Neurosurgery. 2018; 32(2):157-164 7 85. Lu N, Jackson D, Luke S, Festic E, Hanel RA, Freeman WD. Intraventricular 8 nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: 9 assessment of 90 days outcome. Neurocritical Care. 2012; 16(3):368-375 10 86. Luo W, Qiu S, Ma W. Clinical study of magnesium sulphate on delayed cerebral 11 vasospasm after subarachnoid haemorrhage. Journal of Clinical Neurology. 1996; 12 9(4):244-245 13 87. Macdonald RL, Jaja B, Cusimano MD, Etminan N, Hanggi D, Hasan D et al. SAHIT 14 Investigators-on the outcome of some subarachnoid hemorrhage clinical trials. 15 Translational Stroke Research. 2013; 4(3):286-296 16 88. Maldonado JA, Milchorena G, López-Camacho O, Madrazo I. Management using 17 nimodipine of cerebral vasospasm secondary to subarachnoid hemorrhage caused 18 by rupture of an intracranial aneurysm. Archivos de Investigación Medica. 1990; 19 21(2):179-187 20 89. Mortimer AM, Steinfort B, Faulder K, Bradford C, Finfer S, Assaad N et al. The detrimental clinical impact of severe angiographic vasospasm may be diminished by 21 22 maximal medical therapy and intensive endovascular treatment. Journal of 23 Neurointerventional Surgery. 2015; 7(12):881-887 24 90. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the 25 management of patients with aneurysmal subarachnoid hemorrhage: a randomized, 26 placebo-controlled, dose-adapted trial. Surgical Neurology. 2008; 69(1):33-39; 27 discussion 39 28 91. Mutoh T. Early versus minimally-invasive goal-directed therapy on delayed cerebral 29 ischemia and outcome after subarachnoid hemorrhage [UMIN000007509]. 2012. 30 Available from: https://upload.umin.ac.jp/cgi-open-31 bin/ctr e/ctr view.cgi?recptno=R000008863 Last accessed: 10/08/2019. 32 92. Mutoh T, Ishikawa T, Kazumata K, Matsumoto K, Taki Y, Suzuki A. Dobutamine 33 versus mirlinone for intensive hemodynamic augmentation to relieve clinical delayed 34 cerebral ischemia after subarachnoid hemorrhage. Stroke. 2014; 45(Suppl 1):ATP355 35 93. Mutoh T, Kazumata K, Terasaka S, Taki Y, Suzuki A, Ishikawa T. Early intensive 36 versus minimally invasive approach to postoperative hemodynamic management 37 after subarachnoid hemorrhage. Stroke. 2014; 45(5):1280-1284 38 94. Narayan V, Pendharkar H, Devi BI, Bhat DI, Shukla DP. Aggressive management of 39 vasospasm with direct intra-arterial nimodipine therapy. Neurology India. 2018; 40 66(2):416-422 41 95. National Institute for Health and Care Excellence. Developing NICE guidelines: the 42 manual [updated October 2018]. London. National Institute for Health and Care 43 Excellence, 2014. Available from: 44 http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview 45 96. NHS England and NHS Improvement. National cost collection for the NHS 2018-19. 46 2019. Available from: https://improvement.nhs.uk/resources/national-cost-collection/ Last accessed: 01/04/2020. 47

1 97. Nibbelink DW, Sahs AL, Knowler LA. Antihypertensive and antifibrinolytic medications 2 in subarachnoid hemorrhage and their relation to cerebral vasospasm. 'In:' Smith RR, 3 Robertson JT, editors. Subarachnoid hemorrhage and cerebrovascular spasm. 4 Springfield: Charles C Thomas. 1975. p. 177-205. 5 98. Nogueira RG, Bodock MJ, Koroshetz WJ. High-dose bosentan in the prevention and 6 treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label 7 feasibility study. Neurocritical Care. 2007; 7:194-202 99. Otten ML, Mocco J, Connolly ES, Jr., Solomon RA. A review of medical treatments of 8 9 cerebral vasospasm. Neurological Research. 2008; 30(5):444-449 Pala A, Schick J, Klein M, Mayer B, Schmitz B, Wirtz CR et al. The influence of 10 100. 11 nimodipine and vasopressors on outcome in patients with delayed cerebral ischemia after spontaneous subarachnoid hemorrhage. Journal of Neurosurgery. 2019; 12 13 132(4):1096-1104 14 101. Patel AS, Griessenauer CJ, Gupta R, Adeeb N, Foreman PM, Shallwani H et al. Safety and efficacy of noncompliant balloon angioplasty for the treatment of 15 16 subarachnoid hemorrhage-induced vasospasm: a multicenter study. World Neurosurgery. 2017; 98:189-197 17 18 102. Polin RS, Coenen VA, Hansen CA, Shin P, Baskaya MK, Nanda A et al. Efficacy of 19 transluminal angioplasty for the management of symptomatic cerebral vasospasm 20 following aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 2000; 21 92(2):284-290 22 103. Polin RS, Hansen CA, German P, Chadduck JB, Kassell NF. Intra-arterially 23 administered papaverine for the treatment of symptomatic cerebral vasospasm. 24 Neurosurgery. 1998; 42(6):1256-1264; discussion 1264-1257 25 104. Robinson MJ, Teasdale GM. Calcium antagonists in the management of 26 subarachnoid haemorrhage. Cerebrovascular and Brain Metabolism Reviews. 1990; 27 2(3):205-226 28 105. Romero CM, Morales D, Reccius A, Mena F, Prieto J, Bustos P et al. Milrinone as a 29 rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal 30 subarachnoid hemorrhage. Neurocritical Care. 2009; 11(2):165-171 Roy B, McCullough LD, Dhar R, Grady J, Wang YB, Brown RJ. Comparison of initial 31 106. 32 vasopressors used for delayed cerebral ischemia after aneurysmal subarachnoid 33 hemorrhage. Cerebrovascular Diseases. 2017; 43(5-6):266-271 34 107. Sadamasa N, Yoshida K, Narumi O, Chin M, Yamagata S. Milrinone via lumbar 35 subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage. 36 Neurocritical Care. 2014; 21(3):470-475 37 108. Samseethong T, Suansanae T, Veerasarn K, Liengudom A, Suthisisang C. Impact of early versus late intravenous followed by oral nimodipine treatment on the occurrence 38 39 of delayed cerebral ischemia among patients with aneurysm subarachnoid 40 hemorrhage. Annals of Pharmacotherapy. 2018; 52(11):1061-1069 41 109. Santillan A, Knopman J, Zink W, Patsalides A, Gobin YP. Transluminal balloon 42 angioplasty for symptomatic distal vasospasm refractory to medical therapy in 43 patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2011; 69(1):95-44 101; discussion 102 45 110. Sehy JV, Holloway WE, Lin SP, Cross DT, 3rd, Derdeyn CP, Moran CJ. Improvement 46 in angiographic cerebral vasospasm after intra-arterial verapamil administration. 47 American Journal of Neuroradiology. 2010; 31(10):1923-1928

1 2 3	111.	Shankar JJS, Dos Santos MP, Deus-Silva L, Lum C. Angiographic evaluation of the effect of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal subarachnoid hemorrhage. Neuroradiology. 2011; 53(2):123-128
4 5 6 7	112.	Sokolowski JD, Chen CJ, Ding D, Buell TJ, Raper DM, Ironside N et al. Endovascular treatment for cerebral vasospasm following aneurysmal subarachnoid hemorrhage: predictors of outcome and retreatment. Journal of Neurointerventional Surgery. 2018; 10(4):367-374
8 9 10	113.	Son YJ, Han DH, Kang HS, Cho WS, Park JH. Comparison of the efficacy of intraarterial papaverine and nimodipine infusion for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2010; 41(4):e328
11 12 13 14	114.	Stuart D, Christian R, Uschmann H, Palokas M. Effectiveness of intrathecal nicardipine on cerebral vasospasm in non-traumatic subarachnoid hemorrhage: a systematic review. JBI Database Of Systematic Reviews And Implementation Reports. 2018; 16(10):2013-2026
15 16 17	115.	Suarez JI, Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Magnesium sulfate administration in subarachnoid hemorrhage. Neurocritical Care. 2011; 15(2):302-307
18 19 20 21	116.	Tejada JG, Taylor RA, Ugurel MS, Hayakawa M, Lee SK, Chaloupka JC. Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid hemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. American Journal of Neuroradiology. 2007; 28(5):844-848
22 23	117.	Treggiari MM, Deem S. Which H is the most important in triple-H therapy for cerebral vasospasm? Current Opinion in Critical Care. 2009; 15(2):83-86
24 25 26	118.	van den Bergh WM. Magnesium in subarachnoid haemorrhage. 'In:' Vink R, Nechifor M, editors. Magnesium in the Central Nervous System [Internet]. Adelaide (AU): University of Adelaide Press. 2011.
27 28	119.	van den Bergh WM. Magnesium in subarachnoid haemorrhage: proven beneficial? Magnesium Research. 2009; 22(3):121-126
29 30 31	120.	van den Bergh WM, Algra A, Rinkel GJ, Group MS. Magnesium and aspirin treatment in patients with subarachnoid haemorrhage. Comparison of effects after endovascular and neurosurgical aneurysm occlusion. Journal of Neurology. 2009; 256(2):213-216
32 33 34	121.	van den Bergh WM, van de Water JM, Hoff RG, Algra A, Rinkel GJ. Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage. Neurocritical Care. 2008; 8(3):413-417
35 36 37	122.	Velat GJ, Kimball MM, Mocco JD, Hoh BL. Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurgery. 2011; 76(5):446-454
38 39 40 41	123.	Veldeman M, Hollig A, Clusmann H, Stevanovic A, Rossaint R, Coburn M. Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review. British Journal of Anaesthesia. 2016; 117(1):17-40
42 43 44 45	124.	Venkatraman A, Khawaja AM, Gupta S, Hardas S, Deveikis JP, Harrigan MR et al. Intra-arterial vasodilators for vasospasm following aneurysmal subarachnoid hemorrhage: a meta-analysis. Journal of Neurointerventional Surgery. 2018; 10(4):380-387

1 125. Vergouw LJM, Egal M, Bergmans B, Dippel DWJ, Lingsma HF, Vergouwen MDI et al. 2 High early fluid input after aneurysmal subarachnoid hemorrhage: combined report of 3 association with delayed cerebral ischemia and feasibility of cardiac output-guided 4 fluid restriction. Journal of Intensive Care Medicine. 2017; 35(2):161-169 126. Vergouwen MD. Magnesium sulfate for aneurysmal subarachnoid hemorrhage: the 5 6 end of the road or more trials? Critical Care. 2011; 15(2):140 7 127. Webb A, Kolenda J, Martin K, Wright W, Samuels O. The effect of intraventricular administration of nicardipine on mean cerebral blood flow velocity measured by 8 9 transcranial Doppler in the treatment of vasospasm following aneurysmal 10 subarachnoid hemorrhage. Neurocritical Care. 2010; 12(2):159-164 11 128. Weyer GW, Nolan CP, Macdonald RL. Evidence-based cerebral vasospasm 12 management. Neurosurgical Focus. 2006; 21(3):E8 13 129. Williams G, Maroufy V, Rasmy L, Brown D, Yu D, Zhu H et al. Vasopressor treatment 14 and mortality following nontraumatic subarachnoid hemorrhage: a nationwide 15 electronic health record analysis. Neurosurgical Focus. 2020; 48(5):E4 Wong GK, Boet R, Poon WS, Chan MT, Gin T, Ng SC et al. Intravenous magnesium 16 130. 17 sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and 18 meta-analysis. Critical Care. 2011; 15(1):R52 19 131. Yao Z, Hu X, You C. Endovascular therapy for vasospasm secondary to 20 subarachnoid hemorrhage: a meta-analysis and systematic review. Clinical 21 Neurology and Neurosurgery. 2017; 163:9-14 22 132. Zhang C, Zhao S, Zang Y, Zhao W, Song Q, Feng S et al. Magnesium sulfate in 23 combination with nimodipine for the treatment of subarachnoid hemorrhage: a 24 randomized controlled clinical study. Neurological Research. 2018; 40(4):283-291 25 133. Zhang YP, Shields LB, Yao TL, Dashti SR, Shields CB. Intrathecal treatment of 26 cerebral vasospasm. Journal of Stroke and Cerebrovascular Diseases. 2013; 27 22(8):1201-1211 28 134. Zhu Y. Clinical study of nimodipine in preventing and treating cerebral vasospasm 29 after subarachnoid hemorrhage. Chinese Journal of Primary Medicine and Pharmacy. 30 2001; 8(3):256-257 31 32 33

1 Appendices

2 Appendix A: Review protocols

3 Table 10: Review protocol: Managing DCI

ID	Field	Content
0.	PROSPERO registration number	CRD42019146783
1.	Review title	What is the clinical and cost effectiveness of options for managing delayed cerebral ischaemia?
2.	Review question	What is the clinical and cost effectiveness of options for managing delayed cerebral ischaemia?
3.	Objective	To determine which intervention to manage delayed cerebral ischaemia is the most clinically and cost-effective. Delayed cerebral ischemia is recognised as a serious complication of aneurysmal subarachnoid haemorrhage associated with increased morbidity and mortality.
4.	Searches	The following databases will be searched:
		 Cochrane Central Register of Controlled Trials (CENTRAL)
		 Cochrane Database of Systematic Reviews (CDSR)
		• Embase
		• MEDLINE
		Searches will be restricted by:
		• English language only
		The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.
		The full search strategies will be published in the final review.
5.	Condition or domain being studied	Aneurysmal subarachnoid haemorrhage
6.	Population	Inclusion: Adults (16 and older) with a confirmed delayed cerebral ischemia following a subarachnoid haemorrhage caused by a suspected or confirmed ruptured aneurysm.
		Exclusion:
		 Adults with subarachnoid haemorrhage caused by head injury, ischaemic stroke or an arteriovenous malformation.
		 Children and young people aged 15 years and younger.
7.	Intervention/Exposure/Test	 Vasopressors (hypertensive treatment)

		Newsday align
		 o Noradrenaline Matereminal
		o Metaraminol
		Inotrope
		∘ Adrenaline
		 Dobutamine
		 o Milrinone
		• Fluid therapy (crystalloid, colloid, albumin)
		∘ Hypervolemia
		∘ Euvolemia
		 Intra-arterial vasodilator medication
		Angioplasty
		 Combination of above
8.	Comparator/Reference	Comparators:
0.	standard/Confounding factors	• To each other
		Within class
		To no treatment
9.	Types of study to be included	Randomised controlled trials (RCTs),
		systematic reviews of RCTs.
		If insufficient RCT evidence is available, non-
		randomised studies will be considered if they
		adjust for key confounders (age), starting with
10		prospective cohort studies.
10.	Other exclusion criteria	Exclusions:
		Non- English language studies
		 Abstracts will be excluded as it is expected there will be sufficient full text published
		studies available.
11.	Context	
12.	Primary outcomes (critical	Mortality
	outcomes)	 Health and social-related quality of life (any validated measure)
		 Degree of disability or dependence in daily
		activities, (any validated measure e.g. e.g.
		Modified Rankin Scale and patient-reported
		outcome measures)
13.	Secondary outcomes (important	 Subsequent subarachnoid haemorrhage
	outcomes)	 Return to usual daily activity e.g. work
		Cerebral infarction
		Intracranial bleed
		Cardiopulmonary complications
		 Length of stay in hospital
		Outcomes will be grouped at <30 days, 30days-
		6 months, 6-12 months, and at yearly time- points thereafter.
14.	Data extraction (selection and	
14.	coding)	EndNote will be used for reference
		management, sifting, citations and bibliographies. All references identified by the
		searches and from other sources will be
		searcnes and from other sources will be

		screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above. EviBASE will be used for data extraction. If not an intervention review, add: A standardised form will be used to extract data
15.	Pick of bias (quality) assessment	from studies (see <u>Developing NICE guidelines:</u> <u>the manual</u> section 6.4).
15.	Risk of bias (quality) assessment	Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.
		 Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS)
		 Randomised Controlled Trial: Cochrane RoB (2.0)
		 Non randomised study, including cohort studies: Cochrane ROBINS-I
		10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:
		 papers were included /excluded appropriately
		 a sample of the data extractions
		 correct methods are used to synthesise data
		 a sample of the risk of bias assessments
		Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.
16.	Strategy for data synthesis	 Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5). GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome. The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group http://www.gradeworkinggroup.org/

		 Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome. Subgroups will be investigated separately if meta-analysed results show heterogeneity. 			
17.	Analysis of sub-groups	Strata: • n/a Subgroups: • Grade • Good grade • Bad grade			
18.	Type and method of review	\boxtimes	Intervent	tion	
			Diagnos	tic	
			Prognos	tic	
			Qualitati	ve	
			Epidemi	ologic	
			Service	Delivery	
			Other (p	lease speci	fy)
19.	Language	English			
20.	Country	England			
21.	Anticipated or actual start date				
22. 23.	Anticipated completion date Stage of review at time of this	3 February 2021			
20.	submission	Review stage Preliminary searches		Started	Completed
		Piloting of the study selection process			
			eening esults gibility	v	V
		Data extra	ction	~	•
		Risk of bias (quality) assessment Data analysis		•	V
				v	v
24.	Named contact	5a. Named contact			
		National Guideline Centre			
		5b Named SAH@nice		-mail	
		5e Organisational affiliation of the review		ne review	

		National Institute for Health and Care Excellence (NICE) and the National Guideline Centre
25.	Review team members	From the National Guideline Centre: • Ms Gill Ritchie • Mr Ben Mayer • Mr Audrius Stonkus • Mr Vimal Bedia • Ms Emma Cowles • Ms Jill Cobb • Ms Amelia Unsworth
26.	Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.
27.	Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
28.	Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of <u>Developing NICE guidelines: the</u> <u>manual</u> . Members of the guideline committee are available on the NICE website.
29.	Other registration details	
30.	Reference/URL for published protocol	
31.	Dissemination plans	 NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: notifying registered stakeholders of publication publicing the guideline through NICE's
		 publicising the guideline through NiCE's newsletter and alerts issuing a press release or briefing as
		appropriate, posting news articles on the

		NICE website, using social media channels, and publicising the guideline within NICE.	
32.	Keywords	Subarachnoid haemorrhage; delayed cerebral ischaemia	
33.	Details of existing review of same topic by same authors	None	
34.	Current review status		Ongoing
			Completed but not published
			Completed and published
			Completed, published and being updated
			Discontinued
35	Additional information		
36.	Details of final publication	www.nice.org.uk	

1 2

1 Table 11: Health economic review protocol

Review	lith economic review protocol
question	All questions where health economic evidence applicable
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	 Populations, interventions and comparators must be as specified in the clinical review protocol above.
	• Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).
	 Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)
	 Unpublished reports will not be considered unless submitted as part of a call for evidence. Studian must be in English
Saarah	Studies must be in English. A backth according to the undertaken using non-ulation energies terms
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.
	Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual. ⁹⁵
	Inclusion and exclusion criteria
	• If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.
	 If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
	• If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.
	Where there is discretion
	The health economist will decide based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.
	The health economist will be guided by the following hierarchies. Setting:
	 UK NHS (most applicable). OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden). OECD countries with predominantly private health insurance systems (for example, for example, for example).
	Switzerland).

 Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost-utility analysis (most applicable).
- Other type of full economic evaluation (cost-benefit analysis, cost-effectiveness analysis, cost-consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations. *Year of analysis:*
- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

• The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

2 Appendix B: Literature search strategies

3 This literature search strategy was used for the following review;

- What is the clinical and cost effectiveness of options for managing delayed cerebral ischaemia?
- 6 The literature searches for this review are detailed below and complied with the methodology
 7 outlined in Developing NICE guidelines: the manual⁹⁵
- 8 For more information, please see the Methods Report published as part of the accompanying9 documents for this guideline.

B.1¹⁰ Clinical search literature search strategy

- 11 Searches were constructed using a PICO framework where population (P) terms were
- 12 combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are
- 13 rarely used in search strategies for interventions as these concepts may not be well
- 14 described in title, abstract or indexes and therefore difficult to retrieve. Search filters were
- 15 applied to the search where appropriate.

16 Table 12: Database date parameters and filters used

Database	Dates searched	Search filter used			
Medline (OVID)	1946 – 24 June 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies Diagnostic tests studies			
Embase (OVID)	1974 – 24 June 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies			

Database	Dates searched	Search filter used
		Diagnostic tests studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 6 of 12 CENTRAL to 2020 Issue 6 of 12	None

1 Medline (Ovid) search terms

1.	exp Subarachnoid Hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp Intracranial Aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter/
8.	editorial/
9.	news/
10.	exp historical article/
11.	Anecdotes as Topic/
12.	comment/
13.	case report/
14.	(letter or comment*).ti.
15.	or/7-14
16.	randomized controlled trial/ or random*.ti,ab.
17.	15 not 16
18.	animals/ not humans/
19.	exp Animals, Laboratory/
20.	exp Animal Experimentation/
21.	exp Models, Animal/
22.	exp Rodentia/
23.	(rat or rats or mouse or mice).ti.
24.	or/17-23
25.	6 not 24
26.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
27.	25 not 26
28.	limit 27 to English language
29.	randomized controlled trial.pt.
30.	controlled clinical trial.pt.
31.	randomi#ed.ti,ab.
32.	placebo.ab.
33.	randomly.ti,ab.
34.	Clinical Trials as topic.sh.
35.	trial.ti.
36.	or/29-35

37.	Meta-Analysis/	
38.	exp Meta-Analysis as Topic/	
39.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.	
40.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.	
41.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.	
42.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.	
43.	(search* adj4 literature).ab.	
44.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.	
45.	cochrane.jw.	
46.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.	
47.	or/37-46	
48.	Epidemiologic studies/	
49.	Observational study/	
50.	exp Cohort studies/	
51.	(cohort adj (study or studies or analys* or data)).ti,ab.	
52.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.	
53.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.	
54.	Controlled Before-After Studies/	
55.	Historically Controlled Study/	
56.	Interrupted Time Series Analysis/	
57.	(before adj2 after adj2 (study or studies or data)).ti,ab.	
58.	exp case control study/	
59.	case control*.ti,ab.	
60.	Cross-sectional studies/	
61.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.	
62.	or/48-61	
63.	exp "Sensitivity and Specificity"/	
64.	(sensitivity or specificity).ti,ab.	
65.	((pre test or pretest or post test) adj probability).ti,ab.	
66.	(predictive value* or PPV or NPV).ti,ab.	
67.	likelihood ratio*.ti,ab.	
68.	likelihood function/	
69.	((area under adj4 curve) or AUC).ti,ab.	
70.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.	
71.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.	
72.	gold standard.ab.	
73.	or/63-72	
74.	28 and (36 or 47 or 62 or 73)	
75.	Vasospasm, Intracranial/	
76.	delayed cerebral isch?emia.ti,ab.	

77.	((cerebral or cerebrovascular or intracranial or intra-cranial) adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
78.	(Cerebral adj (artery or arterial) adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
79.	((intracranial or intra-cranial) adj vascular adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
80.	DCI.ti,ab.
81.	or/75-80
82.	74 and 81

1 Embase (Ovid) search terms

1.	*subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	Case report/ or Case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	Nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental animal/
19.	Animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
25.	23 not 24
26.	limit 25 to English language
27.	exp "sensitivity and specificity"/
28.	(sensitivity or specificity).ti,ab.
29.	((pre test or pretest or post test) adj probability).ti,ab.
30.	(predictive value* or PPV or NPV).ti,ab.
31.	likelihood ratio*.ti,ab.
32.	((area under adj4 curve) or AUC).ti,ab.
33.	(receive* operat* characteristic* or receive* operat* curve* or ROC curve*).ti,ab.

34.	(diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.	
35.	diagnostic accuracy/	
36.	diagnostic test accuracy study/	
37.	gold standard.ab.	
38.	or/27-37	
39.	Clinical study/	
40.	Observational study/	
41.	family study/	
42.	longitudinal study/	
43.	retrospective study/	
44.	prospective study/	
45.	cohort analysis/	
46.	follow-up/	
47.	cohort*.ti,ab.	
48.	46 and 47	
49.	(cohort adj (study or studies or analys* or data)).ti,ab.	
50.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.	
51.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies review or analys* or cohort* or data)).ti,ab.	
52.	(before adj2 after adj2 (study or studies or data)).ti,ab.	
53.	exp case control study/	
54.	case control*.ti,ab.	
55.	cross-sectional study/	
56.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.	
57.	or/39-45,48-56	
58.	random*.ti,ab.	
59.	factorial*.ti,ab.	
60.	(crossover* or cross over*).ti,ab.	
61.	((doubl* or singl*) adj blind*).ti,ab.	
62.	(assign* or allocat* or volunteer* or placebo*).ti,ab.	
63.	crossover procedure/	
64.	single blind procedure/	
65.	randomized controlled trial/	
66.	double blind procedure/	
67.	or/58-66	
68.	systematic review/	
69.	meta-analysis/	
70.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.	
71.	((systematic or evidence) adj3 (review* or overview*)).ti,ab.	
72.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.	
73.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.	
74.	(search* adj4 literature).ab.	

75.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
76.	cochrane.jw.
77.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
78.	or/68-77
79.	26 and (38 or 57 or 67 or 78)
80.	brain vasospasm/
81.	delayed cerebral isch?emia.ti,ab.
82.	((cerebral or cerebrovascular or intracranial or intra-cranial) adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
83.	(Cerebral adj (artery or arterial) adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
84.	((intracranial or intra-cranial) adj vascular adj (spasm* or angiospasm* or vasospasm*)).ti,ab.
85.	DCI.ti,ab.
86.	or/80-85
87.	79 and 86

1 Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Subarachnoid Hemorrhage] explode all trees
#2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) near/3 (hemorrhag* or haemorrhag* or bleed* or blood*)):ti,ab
#3.	(SAH or aSAH):ti,ab
#4.	MeSH descriptor: [Intracranial Aneurysm] explode all trees
#5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) near/3 (aneurysm* or aneurism* or hematoma* or haematoma*)):ti,ab
#6.	(or #1-#5)
#7.	MeSH descriptor: [Vasospasm, Intracranial] this term only
#8.	delayed cerebral isch*emia:ti,ab
# 9.	((cerebral or cerebrovascular or intracranial or intra-cranial) NEXT (spasm* or angiospasm* or vasospasm*)):ti,ab
#10.	(Cerebral adj (artery or arterial) NEXT (spasm* or angiospasm* or vasospasm*)):ti,ab
#11.	((intracranial or intra-cranial) NEXT vascular NEXT (spasm* or angiospasm* or vasospasm*)):ti,ab
#12.	dci:ti,ab
#13.	(or #7-#12)

B.2₂ Health Economics literature search strategy

- 3 Health economic evidence was identified by conducting a broad search relating to
- 4 subarachnoid haemorrhage population in NHS Economic Evaluation Database (NHS EED -
- 5 this ceased to be updated after March 2015) and the Health Technology Assessment
- 6 database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the
- 7 Centre for Research and Dissemination (CRD). Additional searches were run on Medline and
- 8 Embase.

9 Table 13: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline	2003 – 23 June 2020	Exclusions Health economics studies

Database	Dates searched	Search filter used
Embase	2003 – 23 June 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 23 June 2020 NHSEED - Inception to March 2015	None

1 Medline (Ovid) search terms

exp Subarachnoid Hemorrhage/
((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
(SAH or aSAH).ti,ab.
exp Intracranial Aneurysm/
((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
or/1-5
letter/
editorial/
news/
exp historical article/
Anecdotes as Topic/
comment/
case report/
(letter or comment*).ti.
or/7-14
randomized controlled trial/ or random*.ti,ab.
15 not 16
animals/ not humans/
exp Animals, Laboratory/
exp Animal Experimentation/
exp Models, Animal/
exp Rodentia/
(rat or rats or mouse or mice).ti.
or/17-23
6 not 24
limit 25 to English language
Economics/
Value of life/
exp "Costs and Cost Analysis"/
exp Economics, Hospital/
exp Economics, Medical/
Economics, Nursing/
Economics, Pharmaceutical/
exp "Fees and Charges"/
exp Budgets/

36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/27-42
44.	26 and 43

1 Embase (Ovid) search terms

1.	subarachnoid hemorrhage/
2.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)).ti,ab.
3.	(SAH or aSAH).ti,ab.
4.	exp intracranial aneurysm/
5.	((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial or brain or saccular or berry or wide-neck*) adj3 (aneurysm* or aneurism* or hematoma* or haematoma*)).ti,ab.
6.	or/1-5
7.	letter.pt. or letter/
8.	note.pt.
9.	editorial.pt.
10.	case report/ or case study/
11.	(letter or comment*).ti.
12.	or/7-11
13.	randomized controlled trial/ or random*.ti,ab.
14.	12 not 13
15.	animal/ not human/
16.	nonhuman/
17.	exp Animal Experiment/
18.	exp Experimental Animal/
19.	animal model/
20.	exp Rodent/
21.	(rat or rats or mouse or mice).ti.
22.	or/14-21
23.	6 not 22
24.	limit 23 to English language
25.	health economics/
26.	exp economic evaluation/
27.	exp health care cost/
28.	exp fee/
29.	budget/
30.	funding/
31.	budget*.ti,ab.

32.	cost*.ti.
33.	(economic* or pharmaco?economic*).ti.
34.	(price* or pricing*).ti,ab.
35.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
36.	(financ* or fee or fees).ti,ab.
37.	(value adj2 (money or monetary)).ti,ab.
38.	or/25-37
39.	24 and 38


1 NHS EED and HTA (CRD) search terms

MeSH DESCRIPTOR Subarachnoid Hemorrhage EXPLODE ALL TREES
MeSH DESCRIPTOR Intracranial Hemorrhages EXPLODE ALL TREES
(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (hemorrhag* or haemorrhag* or bleed* or blood*)))
((SAH or aSAH))
#1 OR #2 OR #3 OR #4
MeSH DESCRIPTOR Aneurysm EXPLODE ALL TREES
((aneurysm* or hematoma* or haematoma*))
#6 OR #7
MeSH DESCRIPTOR Intracranial Aneurysm EXPLODE ALL TREES
(((subarachnoid* or arachnoid* or cerebral or intracranial or intra-cranial) adj3 (aneurysm* or hematoma* or haematoma*)))
#9 OR #10
MeSH DESCRIPTOR Aneurysm, ruptured
(((ruptur* or weak* or brain or trauma*) adj3 (aneurysm* or hematoma* or haematoma*)))
#12 OR #13
(#5 or #8 or #11 or #14)

2

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of management of DCI



1 Appendix D: Clinical evidence tables

Study	Gathier 2018 ⁴⁷
Study type	RCT (Patient randomised; Parallel)
Number of studies (number of participants) (n=41)
Countries and setting	Conducted in Netherlands; Setting: Magnus Institute of Neurosciences, Department of Neurosurgery and Neurology, University Medical Centre Utrecht, The Netherlands
Line of therapy	Adjunctive to current care
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Eligible patients for trial participation include all patients above 18 years with an aneurysmal SAH who develop delayed cerebral ischemia (DCI based on a decrease of at least one point on the Glasgow Coma Scale sum-score, and/or the development of new focal neurological deficits according to the NIHSS, diagnosed by a neurologist, neurosurgeon, or intensivist, unless the deterioration does not reflect DCI as evaluated by the treating physician)
Exclusion criteria	Coexisting severe head injury, Perimesencephalic haemorrhage, A history of a ventricular cardiac rhythm disorder or heart failure necessitating medical treatment, Likely transfer to another hospital, not participating in the trial, soon after treatment for the aneurysm, Moribund, Pregnancy No informed consent; Another cause for neurological deterioration, e.g.: (Increasing) hydrocephalus, Recurrent bleeding, Clinical signs of epilepsy, Severe infectious disease with associated decrease in level of consciousness, Hypoglycaemia, defined as serum glucose <3.0 mmol/l, Hyponatremia, defined as serum sodium <125 mmol/l, Metabolic encephalopathy due to renal or hepatic failure, An untreated symptomatic aneurysm, A spontaneous mean arterial pressure above 120 mmHg at the moment of randomization, Any contraindication for induced hypertension.
Recruitment/selection of patients	Patients with aneurysmal subarachnoid haemorrhage who go on to develop delayed cerebral ischemia.

Age - Mean (SD): Hypertension: 63 (12); Control: 57 (10). Gender (M:F): 10/31.
1. Patient grade: Poor grade (Admission WFNS score >3 - Hypertension: 12; No hypertension: 8).
. This trial was prematurely terminated based on the evidence of the Data safety Monitoring Board because of lack of effect on overall cerebral perfusion and slow recruitment resulting in the conclusion that it would be unfeasible to obtain sufficient numbers of included subjects within a reasonable time frame.
No indirectness
(n=21) Intervention 1: Vasopressors (hypertensive treatment) - Noradrenaline. Hypertension needed to be started within 3 hours after the start of clinical symptoms of DCI. Hypertension was induced with fluids and norepinephrine over a central venous line placed for this purpose in the intensive care unit (ICU) according to the local protocol of the participating centre. The treatment was continued until improvement of neurological deficits, occurrence of a complication, a maximum MAP of 130 mmHg, or a systolic blood pressure of 230 mmHg. Clinical improvement within 24 hours was judged by the unblinded treating clinician. In case of clinical improvement, norepinephrine was continued for at least 48 hours and then slowly tapered. In case of recurrence of symptoms during tapering, norepinephrine was restarted and tapering was attempted 24 hours later. In the absence of clinical improvement within 24 hours, norepinephrine was tapered Duration As required . Concurrent medication/care: All patients were treated with oral nimodipine and fluid administration aimed at normovolemia (n=20) Intervention 2: No treatment. In the no hypertension group, hypertension was not induced, but a minimal MAP of 80 mmHg was maintained with fluids and, when necessary, with vasopressors. In the latter case, a central venous line was placed, but otherwise, no central venous lines were used in the no hypertension group. Duration As required. Concurrent medication/care: All patients were treated with oral nimodipine and fluid administration aimed at normovolemia
Academic or government funding (C.S. Gathier is supported by the Dutch Heart Foundation (grant
2009B046) and the Brain Foundation Netherlands (grant 2009(1)- 72).)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NOREPINEPHRINE + FLUIDS versus NO HYPERTENSIVES

Protocol outcome 1: Health and social quality of life

- Actual outcome: Activities of daily living (Barthel Index) at 3 months postintervention; Median (IQR): Hypertension: 20 (10-20); Control: 20 (16-20) Barthel Index 0-20 Top=High is good outcome;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Quality of life (Stroke specific Quality of life) at 3 months postintervention; Median (IQR): Hypertension: 47 (35-55); Control: 49 (35-55) Stroke specific Quality of life Scale Different scales for different domains within questionnaire Top=Unclear;

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: Anxiety & Depression (HADS scale) at 3 months postintervention; Median IQR : Hypertension: 13 (3-13); Control: 8 (4-11));

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

Protocol outcome 2: Degree of disability or dependence in daily activities, (e.g. Modified Rankin Scale and patient-reported outcome measures) - Actual outcome: mRS 0 at 3 months postintervention; Group 1: 0/21, Group 2: 2/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low; Indirectness of outcome: No indirectness;

- Actual outcome: mRS 1 at 3 months postintervention; Group 1: 1/21, Group 2: 4/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

- Low; Indirectness of outcome: No indirectness ;

- Actual outcome: mRS 2 at 3 months postintervention; Group 1: 6/21, Group 2: 3/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

- Low; Indirectness of outcome: No indirectness ;

- Actual outcome: mRS 3 at 3 months postintervention; Group 1: 2/21, Group 2: 3/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

- Low; Indirectness of outcome: No indirectness ;

- Actual outcome: mRS 4 at 3 months postintervention; Group 1: 3/21, Group 2: 3/20

Risk of bias: All domain - High, Selection - Low, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover

- Low; Indirectness of outcome: No indirectness ;

 Actual outcome: mRS 5 at 3 months posting 	tervention; Group 1: 3/21, Group 2: 1/20
Risk of bias: All domain - High, Selection - Lo	w, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover
- Low; Indirectness of outcome: No indirectn	iess ;
- Actual outcome: mRS 6 at 3 months posting	tervention; Group 1: 6/21, Group 2: 4/20
Risk of bias: All domain - High, Selection - Lov - Low; Indirectness of outcome: No indirectn	w, Blinding - High, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover ness ;
Protocol outcomes not reported by the study	Mortality ; Subsequent subarachnoid haemorrhage ; Return to daily activity (e.g. work) ; Cerebral infarction ; Intracranial bleed ; Cardiopulmonary complication ; Length of hospital stay
Comments	Trial stopped prematurely due to difficulties with participant recruitment and lack of clinical efficacy.

> NICE 2000

Polin 1998 ¹⁰³					
Retrospective cohort analysis – sub-study of RCT (Patient randomised; Parallel)					
(n=31)					
Conducted in USA; Setting: 14 medical centres across northern America					
Adjunctive to current care					
Intervention + follow up:					
Adequate method of assessment/diagnosis					
Overall					
Not applicable					
Patients who have been treated for subarachnoid haemorrhage that have symptomatic vasospasm					
prophylactic treatment with papaverine for angiographic vasospasm without clinical symptoms					
Age - Mean (range): 56.7 years (40-70). Gender (M:F): 12/19.					
1. Patient grade: Not stated / Unclear ((Papaverine group only): WFNS I - II: 19; III - V: 12).					
All patients were part of the North American Tirilizad Trial.					
Participants were matched with patients from the same trial who exhibited similar clinical characteristics (including age, degree of vasospasm and the GCS scores) but received medical management alone for vasospasm.					
No indirectness					
(n=31) Intervention 1: Combination of interventions. Patients were treated with 0.09% (90mg in 100ml) to a higher dose of 0.8% (800mg in 100ml) for each vascular territory. Duration Unclear. Concurrent medication/care: As part of the main clinical trial, 14 patients had received placebo (vehicle), 6 received 2mg/kg/day Tirilizad and 11 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given Indirectness: No indirectness					
(n=62) Intervention 2: No treatment. Patients were matched to the Papaverine cohort by gender, same dose					

		of study drug, age within 10 years and degree of arterial narrowing Duration Unclear . Concurrent medication/care: As part of the main clinical trial, 14 patients had received placebo (vehicle), 6 received 2mg/kg/day Tirilizad and 11 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given Indirectness: No indirectness
-unding Funding not stated	Funding	Funding not stated

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: PAPAVERINE versus NO TREATMENT

Protocol outcome 1: Degree of disability or dependence in daily activities, (e.g. Modified Rankin Scale and patient-reported outcome measures) - Actual outcome: Favourable outcome (mRS ≤ 2) at 3 months; Group 1: 14/31, Group 2: 36/62; Comments: results given as percentages (45% papaverine and 56% control had favourable outcome)

Risk of bias: All domain - Very high, Selection - High, Confounding - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, Measurement - High, Crossover - Low; Indirectness of outcome: No indirectness ;

Protocol outcomes not reported by the Mortality; Health and social quality of life; Subsequent subarachnoid haemorrhage; Return to daily activity (e.g. work); Cerebral infarction; Intracranial bleed; Cardiopulmonary complication; Length of hospital stay

Study	Polin 2000 ¹⁰²
Study type	Retrospective cohort analysis – sub-study of RCT (Patient randomised; Parallel)
Number of studies (number of participants)	(n=38)
Countries and setting	Conducted in USA; Setting: 15 medical centres across northern America
Line of therapy	Adjunctive to current care
Duration of study	Intervention + follow up:
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Overall
Subgroup analysis within study	Not applicable
Inclusion criteria	Patients who have been treated for subarachnoid haemorrhage that have symptomatic vasospasm
Exclusion criteria	Patients who may have received papaverine alone for treatment of cerebral vasospasm
Age, gender and ethnicity	Age - Mean (range): 48.1 years (30-77). Gender (M:F): 15/23.
Further population details	1. Patient grade: Not stated / Unclear ((Angioplasty group only) WFNS I or II: 18; III: 8; IV - V: 12).
Extra comments	All patients were part of the North American Tirilizad Trial A conditional logistic regression analysis was performed in which patients were compared with individuals matched for age, sex, dose of study drug, admission neurological grade, and GCS score at the time of angioplasty.
Indirectness of population	No indirectness
Interventions	 (n=83) Intervention 1: No treatment. Patients were matched to the Angioplasty cohort by gender, same dose of study drug, age within 10 years and degree of arterial narrowing. Duration Unclear. Concurrent medication/care: As part of the main clinical trial, 15 patients had received placebo (vehicle), 10 received 2mg/kg/day Tirilizad and 13 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given Indirectness: No indirectness (n=38) Intervention 2: Combination of interventions - (to be reported). Group consisted of patients who had

	NICE SUN		
) UC		Func
	III rinhte		RESU
	rocoriod		Proto - Act and Risk
	2		Mea
<u>7</u>	viont to NL		Prot stud
	○ NIICE 20020 All rights reserved Cubiest to Notice of rights		

	been treated with Angioplasty alone or Angioplasty plus papaverine if symptomatic of cerebral vasospas Duration Unclear. Concurrent medication/care: As part of the main clinical trial, 14 patients had received placebo (vehicle), 6 received 2mg/kg/day Tirilizad and 11 received 6mg/kg/day Tirilizad. For Vasospasm, Nimodipine 60mg every 4 hours was also given Indirectness: No indirectness
Funding	Funding not stated
RESULTS (NUMBERS ANALYSED) AND RISK O	F BIAS FOR COMPARISON: ANGIOPLASTY + PAPAVERINE versus NO TREATMENT

ocol outcome 1: Degree of disability or dependence in daily activities, (e.g. Modified Rankin Scale and patient-reported outcome measures) tual outcome: Favourable outcome (mRS ≤ 2) at 3 months; Group 1: 21/38, Group 2: 50/83; Comments: results given as percentages (53% angioplasty 60% control had favourable outcome)

of bias: All domain - Very high, Selection - High, Confounding - High, Blinding - High, Incomplete outcome data - Low, Outcome reporting - High, asurement - High, Crossover - Low; Indirectness of outcome: No indirectness;


cocol outcomes not reported by the Mortality; Health and social quality of life; Subsequent subarachnoid haemorrhage; Return to daily activity (e.g. work); Cerebral infarction; Intracranial bleed; Cardiopulmonary complication; Length of hospital stay

1

Appendix E: Forest plots

E.12 Intra-arterial vasodilator medication (papaverine) vs 3 Control (no papaverine)

Figure 2: Favourable outcome (mRS ≤2) (3 months). scale 0-6; high score represents poor outcome



4

E.25 Angioplasty vs Control (no angioplasty)

6 Figure 3: Favourable outcome (mRS ≤2) (3 months). Scale 0-6; high score represents
 7 poor outcome



E.31 Norepinephrine + fluids vs Control (no induced 2 hypertension)

3 Figure 4: mRS 0 – no symptoms (3 months)

		Norepinephrine		Norepinephrine		Norepinephrine			ol		Peto Odds Ratio		Peto O	dds Rati	D	
	Study or Subgroup	Events	Events Total		Events Total		Peto, Fixed, 95% CI		Peto, Fix	ced, 95%	CI					
	Gathier 2018	0	21	2	20		0.12 [0.01, 2.02]	•	1	<u> </u>						
								0.01	0.1	1	10	100				
L									Favours Contro	I Favour	s Norepinep	hrine				


5 Figure 5: mRS 1 – no significant disability (3 months)

		Norepinephrine		Norepinephrine Control		Risk Ratio			Risk Ratio			
	Study or Subgroup	Events Total		Events	Total	Weight M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl				
	Gathier 2018	1	21	4	20		0.24 [0.03, 1.95]	-				
								0.01	0.1 *	1 1	0	100
6									Favours Control	Favours Nore	pinep	hrine

7 Figure 6: mRS 2 – slight disability (3 months)

		Norepinep	repinephrine Control Risk Ratio			Risk Ratio		Risl	Ratio			
	Study or Subgroup	Events	Total	Events	Total	Weight M-H, Fixed, 95% Cl M-H, Fixed				ed, 95% Cl		
	Gathier 2018	6	21	3	20		1.90 [0.55, 6.60]	I		1	-	
								0.01	0.1	1	10	100
3									Favours Control	Favours N	lorepiner	ohrine


9 Figure 7: mRS 3 – moderate disability (3 months)



11 Figure 8: mRS 4 - moderate/severe disability (3 months)

		Norepinephrine		Norepinephrine Control			Risk Ratio	Risk Ratio				
	Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% CI	I M-H, Fixed, 95% CI				
	Gathier 2018	3	21	3	20		0.95 [0.22, 4.18]		. — –			
								0.01 0	.1	1 10) 100	
12								Favours No	prepinephrine	Favours Contr	ol	

13 Figure 9: mRS 5 – severe disability (3 months)




14

4

8

15 Figure 10: mRS 6 - dead (3 months)



Appendix F: GRADE tables

2 Table 14: Clinical evidence profile: Intra-arterial vasodilator medication (Papaverine) vs control (no papaverine)

	Quality assessment No of patients Effect					Quality	Importance					
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Papaverine	Control	Relative (95% Cl) Absolute		quanty	importaneo
Favourabl	e outcome (m	RS ≤2)										
		,		no serious indirectness	serious ²	none	14/31 (45.2%)	58.1%	RR 0.78 (0.5 to 1.21)	128 fewer per 1000 (from 290 fewer to 122 more)	⊕000 VERY LOW	CRITICAL

 $\frac{3}{4}$ ¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias $\frac{2}{2}$ Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

5 Table 15: Clinical evidence profile: Angioplasty vs control (no angioplasty)

	Quality assessment						No of patients Effect		Quality	Importance		
No of studies	Dosign	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Angioplasty	Control	Relative			
Favoura	ble outcome (m	RS ≤2)										

1 ¹ Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias ² Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs

3 Table 16: Clinical evidence profile: Norepinephrine + fluids vs control (no induced hypertension)

	Quality assessment				No of patients		Effect		Quality	Importance		
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Norepinephrine + Fluids	Control	Relative (95% Cl)	Absolute		

mRS 0 (3 months)

mRS 1 (3 months)

1	randomised trials				very serious ¹	none	1/21 (4.8%)	20%		152 fewer per 1000 (from 194 fewer to 190 more)		CRITICAL
---	----------------------	--	--	--	------------------------------	------	----------------	-----	--	---	--	----------

mRS 2 (3 months)

			no serious inconsistency		very serious¹	none	6/21 (28.6%)	15%	RR 1.9 (0.55 to 6.6)	135 more per 1000 (from 68 fewer to 840 more)	⊕⊕OO LOW	CRITICAL
mRS 3 (3	months)											
			no serious inconsistency		very serious ¹	none	2/21 (9.5%)	15%	RR 0.63 (0.12 to 3.41)	56 fewer per 1000 (from 132 fewer to 362 more)	⊕⊕OO LOW	CRITICAL
mRS 4 (3	months)											
		no serious risk of bias	no serious inconsistency		very serious ¹	none	3/21 (14.3%)	15%	RR 0.95 (0.22 to 4.18)	8 fewer per 1000 (from 117 fewer to 477 more)	⊕⊕OO LOW	CRITICAL
mRS 5 (3	months)	•		•								
		no serious risk of bias	no serious inconsistency		very serious ¹	none	3/21 (14.3%)	5%	RR 2.86 (0.32 to 25.24)	93 more per 1000 (from 34 fewer to 1000 more)	⊕⊕OO LOW	CRITICAL
mRS 6 (3	months)			·								
		no serious risk of bias	no serious inconsistency		very serious ¹	none	6/21 (28.6%)	20%	RR 1.43 (0.47 to 4.32)	86 more per 1000 (from 106 fewer to 664 more)	⊕⊕OO LOW	CRITICAL

1 ¹ Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.

Appendix G: Health economic evidence 2 selection




Figure 11: Flow chart of health economic study selection for the guideline

* Non-relevant population, intervention, comparison, design or setting; non-English language

1 Appendix H: Health economic evidence tables

2 None.

1 Appendix I: Excluded studies

I.12 Excluded clinical studies

3 Table 17: Studies excluded from the clinical review

Study	Reason for exclusion
Aburto-Murrieta 2012 ¹	Inappropriate study design - Patients not matched and results not adjusted by age
Adami 2018 ²	Inappropriate study design – no relevant outcomes
Ades 1987 ³	Citation only
Akdemir 2009 ⁴	Inappropriate intervention – prophylactic treatment
Allen 1983 ⁶	Inappropriate intervention – prophylactic treatment
Allen 1985 ⁵	Inappropriate population – animal and human study
Andaluz 2002 ⁷	Inappropriate study design – no useable outcomes
Arakawa 2004 ⁸	Inappropriate study design – non comparative / no useable outcomes
Badjatia 2004 ⁹	Inappropriate study design – no relevant outcomes
Barbarawi 200910	Inappropriate intervention – prophylactic treatment
Bashir 2016 ¹¹	Inappropriate study design – non comparative
Biondi 2004 ¹²	Inappropriate study design – non comparative
Boet 2005 ¹³	Inappropriate study design – prophylactic treatment
Boet 2000 ¹⁴	Inappropriate study design – no relevant outcomes
Boulouis 2017 ¹⁵	Systematic review: references checked
Bradford 2013 ¹⁶	Inappropriate intervention – prophylactic treatment
Brandt 1986 ¹⁷	Inappropriate study design – narrative report
Brathwaite 2014 ¹⁸	Inappropriate study design – literature review
Brewer 2001 ¹⁹	Inappropriate study design – no relevant outcomes
Buchheit 1988 ²⁰	Inappropriate study design – no relevant outcomes
Chalouhi 2014 ²¹	Inappropriate study design - Patients not matched and results not adjusted by age
Chaudhry 2017 ²²	Inappropriate study design – non comparative
Chen 2011 ²⁴	Systematic review: references checked
Chen 2020 ²³	Inappropriate population – patients with vasospasm
Cho 2011 ²⁵	Inappropriate study design – no comparison group
Choi 2011 ²⁶	Inappropriate study design – no comparison group
Coyne 1994 ²⁷	Inappropriate study design – no comparison group
Crespy 2019 ²⁸	Inappropriate intervention – non randomized study
Curran 2006 ²⁹	Inappropriate study design – literature review
Dehdashti 2011 ³⁰	Inappropriate study design – non comparative
Desbordes 1989 ³¹	Paper not available
Duman 2017 ³²	Inappropriate study design – non comparative
Ehlert 2016 ³³	Inappropriate study design – unclear methodology and outcomes
Etminan 2015 ³⁴	Inappropriate study design – no comparison group / no relevant outcomes
Feigin 1998 ³⁶	Systematic review: references checked
Feigin 2000 ³⁵	Systematic review: references checked

Study	Reason for exclusion
Feng 2002 ³⁷	Inappropriate study design – no comparison group
Firlik 1997 ³⁸	Inappropriate study design – no comparison group
Fountas 2008 ³⁹	Inappropriate population – vasospasm compared to no vasospasm
Francoeur 2016 ⁴⁰	Inappropriate study design – literature review
Fraticelli 2008 ⁴¹	Inappropriate study design – non comparative
Friedlich 2009 ⁴²	Inappropriate intervention – prophylactic treatment
Frontera 2010 ⁴³	Inappropriate study design – non comparative
Frontera 2011 ⁴⁴	
	Inappropriate study design – non comparative
Gathier 2014 ⁴⁶	Inappropriate study design – trial protocol
Gathier 2017 ⁴⁵	Inappropriate study design -abstract only
Goel 2016 ⁴⁸	Inappropriate study design - Patients not matched and results not adjusted by age
Goodson 2008 ⁴⁹	Inappropriate study design – non comparative
Gross 2017 ⁵⁰	Inappropriate study design – non comparative
Guggiari 1987 ⁵¹	Inappropriate study design -abstract only
Haegens 2018 ⁵²	Inappropriate study design – no relevant outcomes
Hafeez 2019 ⁵³	Systematic review: references checked
Hanggi 2008 ⁵⁴	Inappropriate study design- non comparative
Harada 1995 ⁵⁵	Paper not available
Hasegawa 2016 ⁵⁶	Inappropriate study design – literature review
Hockel 2016 ⁵⁷	Inappropriate study design – non comparative
Hongo 1993 ⁵⁸	Inappropriate study design – literature review
Hosmann 2018 ⁵⁹	Inappropriate study design – no relevant outcomes
Huang 2010 ⁶⁰	Systematic review: references checked
Hui 2005 ⁶¹	Inappropriate study design – non comparative
Iwabuchi 2011 ⁶²	Inappropriate study design – non comparative
Jan 1988 ⁶³	Inappropriate study design - Patients not matched and results not adjusted by age
Jestaedt 2008 ⁶⁴	Inappropriate intervention – no medical intervention
Jun 2010 ⁶⁶	Inappropriate study design -abstract only
Kasuya 2011 ⁶⁷	Inappropriate study design – non comparative
Katoh 1999 ⁶⁸	Inappropriate study design – non comparative
Kerz 2008 ⁶⁹	Inappropriate intervention - statin
Khatri 2011 ⁷⁰	Inappropriate study design – non comparative
Khatri 2011 ⁷¹	Inappropriate study design – non comparative
Kim 2009 ⁷²	Inappropriate study design – non comparative
Kimball 2011 ⁷³	Inappropriate study design – literature review
Kirchengast 2005 ⁷⁴	Inappropriate study design – literature review
Kiser 2013 ⁷⁵	Systematic review: references checked
Koos 1985 ⁷⁶	Inappropriate study design – non comparative
Koyanagi 2018 ⁷⁷	Inappropriate intervention – prophylactic treatment
Lannes 2012 ⁷⁸	Inappropriate study design – no comparison group
Lennihan 2000 ⁷⁹	Inappropriate intervention – prophylactic treatment
Levati 1998 ⁸⁰	Inappropriate study design – literature review
Li 2015 ⁸¹	Inappropriate study design – no relevant outcomes
Liu 2004 ⁸³	Inappropriate study design – no comparison group
	nappropriate study design – no companson group

Liu-Deryke 2006 ¹² Inappropriate study design – literature review Loan 2018 ⁸⁴ Systematic review: references checked Lu 2012 ⁸⁵ Inappropriate population – vasospasm compared to no vasospasm Luo 1996 ⁸⁶ Paper not available Macdonald 2013 ⁹⁷ Inappropriate population low or no vasospasm compared to vasospasm Muich 2015 ⁹⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁹⁰ Inappropriate population on or vasospasm compared to vasospasm Muroi 2012 ⁹¹ Paper not available Mutch 2014 ⁹² Inappropriate intervention – prophylactic treatment Narayan 2018 ⁸⁴ Inappropriate study design – no comparison group Nibbelini 1975 ⁹⁷ Inappropriate study design – no comparison group Often 2008 ⁹⁰ Inappropriate study design – non comparative Pala 2019 ¹⁰⁰ Inappropriate study design – non comparative Patel 2017 ¹⁰¹ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴⁵ Inappropriate study design – non comparative Robinson 1900 ¹⁰⁵ Inappropriate study design – non comparative Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparative Sanseethong 2018 ¹¹² I	Study	Reason for exclusion
Loa 2018 ⁹⁴ Systematic review: references checkedLu 2012 ⁹⁵ Inappropriate population – vasospasm compared to no vasospasmLuo 1996 ⁹⁶ Paper not availableMacdonald 2013 ⁹⁷ Inappropriate study design – literature reviewMaldonado 1990 ⁹⁸ Not in EnglishMortimer 2015 ⁹⁹ Inappropriate population low or no vasospasm compared to vasospasmMuroi 2008 ⁹⁰ Inappropriate intervention – prophylactic treatmentMutoh 2014 ⁹² Inappropriate study design -citation onlyMutoh 2014 ⁹³ Inappropriate study design – no comparison groupNibolenik 1975 ⁹⁷ Inappropriate study design – no comparison groupNogueira 2007 ⁹⁸ Inappropriate study design – no comparison groupOtten 2008 ⁹⁰ Inappropriate study design – non comparativePala 2019 ¹⁰⁰ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRoy 2017 ¹⁰⁵ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSanseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate study design – non comparativeSokolowski 2018 ¹¹⁴ Systematic review: references checkedSuperpriste study design – non comparativeSokolowski 2018 ¹¹⁴ Systematic review: references checked <td></td> <td></td>		
Lu 2012 ⁸⁵ Inappropriate population – vasospasm compared to no vasospasm Luo 1996 ⁸⁶ Paper not available Macdonald 2013 ⁸⁷ Inappropriate study design – literature review Maldonado 1990 ⁸⁶ Not in English Mortimer 2015 ⁸⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁸⁰ Inappropriate intervention – prophylactic treatment Mutoh 2014 ⁹² Inappropriate intervention – prophylactic treatment Mutoh 2014 ⁹³ Inappropriate study design – on comparison group Nibbelink 1975 ⁹⁷ Inappropriate study design – no comparison group Noteira 2007 ⁹⁸⁰ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – non comparative Pala 2017 ¹⁰¹ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴⁴ Systematic review: references checked Romero 2009 ¹⁰⁵ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴⁴ Inappropriate study design – non comparative Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparative Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparative Schalan 2011 ¹⁰⁸ Inappropriate study design –	•	
Luo 1996 ⁴⁶ Paper not available Macdonald 2013 ⁵⁷ Inappropriate study design – literature review Maldonado 1990 ⁵⁸ Not in English Mortimer 2015 ⁵⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁵⁰ Inappropriate intervention – prophylactic treatment Mutoh 2012 ⁴¹ Paper not available Mutoh 2014 ⁴² Inappropriate study design – ot comparison group Nibbelink 1975 ⁶⁷⁷ Inappropriate study design – no comparison group Nibbelink 1975 ⁶⁷⁷ Inappropriate study design – no comparison group Otten 2008 ⁶⁹ Inappropriate study design – non comparison group Otten 2008 ⁶⁹ Inappropriate study design – non comparative Patel 2017 ¹⁰¹ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Romero 2009 ¹⁰⁵ Inappropriate study design – non comparative Roy 2017 ¹⁰⁵ Inappropriate study design – non comparative Santillan 2011 ¹⁰⁹ Inappropriate study design – non comparative Santillan 2011 ¹⁰⁹ Inappropriate study design – non comparative Santillan 2011 ¹⁰⁹ Inappropriate study design – non comparative		•
Macdonald 2013 ⁸⁷ Inappropriate study design – literature review Maldonado 1990 ⁸⁸ Not in English Mortimer 2015 ⁸⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁹⁰ Inappropriate intervention – prophylactic treatment Mutoh 2012 ⁹¹ Paper not available Mutoh 2014 ⁹² Inappropriate study design – no comparison group Nitoh 2014 ⁹³ Inappropriate study design – no comparison group Nitoh 2015 ⁸⁹ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – no comparative Pala 2019 ¹⁰⁰ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Robinson 1990 ¹⁰⁴ Systematic review: references checked Roby 2017 ¹⁰⁶ Inappropriate study design – non comparative Samseethong 2018 ¹⁰⁸ Inappropriate study design – non comparative Samsethong 2018 ¹⁰⁹ Inappropriate study design – non comparative Sokolowski 2018 ¹¹¹ Inappropriate study design – non comparative Sokolowski 2018 ¹¹² Inappropriate study design – non comparative		
Maldonado 1990 ³⁸ Not in English Mortimer 2015 ⁸⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁸⁰ Inappropriate intervention – prophylactic treatment Mutoh 2014 ⁹² Inappropriate study design - citation only Mutoh 2014 ⁹³ Inappropriate study design – no comparison group Nibbelink 1975 ⁹⁷ Inappropriate study design – no comparison group Nibbelink 1975 ⁹⁷ Inappropriate study design – no comparison group Otten 2008 ⁹⁸ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – no comparison group Pala 2017 ¹⁰⁹ Inappropriate study design – non comparative Pala 2017 ¹⁰⁹ Inappropriate study design – non comparative Romero 2009 ¹⁰⁵ Inappropriate study design – non comparative Robisson 1990 ¹⁰⁴ Systematic review: references checked Romero 2009 ¹⁰⁵ Inappropriate study design – non comparative Robisson 1990 ¹⁰⁴ Systematic review: references checked Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparative Samseethong 2018 ¹⁰⁶ Inappropriate study design – non comparative Satistal 2011 ¹¹⁰ Inappropriate study desig		•
Mortimer 2015 ⁸⁹ Inappropriate population low or no vasospasm compared to vasospasm Muroi 2008 ⁹⁰ Inappropriate intervention – prophylactic treatment Mutoh 2012 ⁹¹ Paper not available Mutoh 2014 ⁹² Inappropriate intervention – prophylactic treatment Narayan 2018 ⁹⁴ Inappropriate study design – no comparison group Nibbelink 1975 ⁶⁷⁷ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – no comparison group Otten 2008 ⁹⁹ Inappropriate study design – no comparative Patel 2017 ¹⁰¹ Inappropriate study design – non comparative Patel 2017 ¹⁰¹ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Romero 2009 ¹⁰⁵ Inappropriate study design – non comparative Roy 2017 ¹⁰⁶ Inappropriate study design – non comparative Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparative Sadamasa 2011 ¹⁰⁹ Inappropriate study design – non comparative Sanseethong 2018 ¹⁰⁹ Inappropriate study design – non comparative Sanseethong 2018 ¹⁰⁰ Inappropriate study design – non comparative Sohakar 2011 ¹¹¹¹ Inappropriat		
VasospasmMuroi 2008 ⁹⁰ Inappropriate intervention – prophylactic treatmentMutoh 2012 ⁹¹ Paper not availableMutoh 2014 ⁹² Inappropriate study design - cliation onlyMutoh 2014 ⁹³ Inappropriate study design – no comparison groupNibbelink 1975 ⁹⁷ Inappropriate study design – no comparison groupNibbelink 1975 ⁹⁷ Inappropriate study design – no comparison groupOtten 2008 ⁹⁹ Inappropriate study design – no comparison groupOtten 2008 ⁹⁹ Inappropriate study design – non comparativePatel 2017 ¹⁰¹ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSatamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSokolwski 2011 ¹¹⁰ Inappropriate study design – non comparativeSokolwski 2011 ¹¹¹ Inappropriate study design – non comparativeSokolwski 2018 ¹¹² Inappropriate study design – non comparativeSokolwski 2018 ¹¹² Inappropriate study design – non comparativeSokolwski 2018 ¹¹³ Inappropriate study design – non comparativeSokolwski 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵		-
Mutoh 2012 ²¹ Paper not available Mutoh 2014 ³² Inappropriate study design -citation only Mutoh 2014 ³³ Inappropriate intervention – prophylactic treatment Narayan 2018 ³⁴ Inappropriate study design – no comparison group Nibbelink 1975 ⁹⁷ Inappropriate study design – no comparison group Otten 2008 ⁹⁸ Inappropriate study design – non comparative Pala 2019 ¹⁰⁰ Inappropriate study design – non comparative Patel 2017 ¹⁰¹ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Romero 2009 ¹⁰⁶ Inappropriate study design – non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Roy 2017 ¹⁰⁶ Inappropriate study design – non comparative Roy 2017 ¹⁰⁶ Inappropriate study design – non comparative Samseethong 2018 ¹⁰⁸ Inappropriate study design – non comparative Samsethong 2018 ¹⁰⁹ Inappropriate study design – non comparative Sokolowski 2018 ¹¹¹ Inappropriate study design – non comparative Sokolowski 2018 ¹¹² Inappropriate study design – non comparative Sokolowski 2018 ¹¹² Inappropriate study design – non comparative		
Mutoh 2014 ³² Inappropriate study design - citation only Mutoh 2014 ³³ Inappropriate intervention - prophylactic treatment Narayan 2018 ⁹⁴ Inappropriate study design - no comparison group Nibbelink 1975 ⁹⁷ Inappropriate study design - no comparison group Otten 2008 ⁹⁹ Inappropriate study design - no comparison group Otten 2008 ⁹⁹ Inappropriate study design - non comparative Patel 2017 ¹⁰¹ Inappropriate study design - non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Romero 2009 ¹⁰⁵ Inappropriate study design - non comparative Robinson 1990 ¹⁰⁴ Systematic review: references checked Roy 2017 ¹⁰⁶ Inappropriate study design - non comparative Sadamasa 2014 ¹⁰⁷ Inappropriate study design - non comparative Samseethong 2018 ¹⁰⁶ Inappropriate study design - non comparative Santillan 2011 ¹⁰⁹ Inappropriate study design - non comparative Sokolowski 2018 ¹¹² Inappropriate study design - non comparative Sokolowski 2018 ¹¹³ Inappropriate study design - non comparative Sokolowski 2018 ¹¹⁴ Systematic review: references checked Suarz 2011 ¹¹⁵ Inappropriate study des	Muroi 2008 ⁹⁰	Inappropriate intervention – prophylactic treatment
Mutoh 2014 ⁹³ Inappropriate intervention – prophylactic treatmentNarayan 2018 ⁹⁴ Inappropriate study design – no comparison groupNibbelink 1975 ⁹⁷ Inappropriate study design – no comparison groupOtten 2008 ⁹⁸ Inappropriate study design – no comparison groupOtten 2008 ⁹⁰ Inappropriate study design – non comparativePatel 2017 ¹⁰¹ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁶ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁸ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁹ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁹ Inappropriate study design – non comparativeSatillan 2011 ¹⁰⁹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate study design – non comparativeSokolowski 2018 ¹¹³ Inappropriate study design – non comparativeSon 2010 ¹¹³ Inappropriate study design – non comparativeSolaurez 2011 ¹¹⁵ Systematic review: references checkedTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedVan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate study design – literature reviewVeldeman 2016 ¹²³	Mutoh 2012 ⁹¹	Paper not available
Narayan 2018 ³⁴ Inappropriate study design – no comparison groupNibbelink 1975 ⁹⁷ Inappropriate study design – literature reviewNogueira 2007 ⁹⁸ Inappropriate study design – no comparison groupOtten 2008 ⁹⁹ Inappropriate study design – non comparativePala 2019 ¹⁰⁰ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁸ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSantillan 2011 ¹⁰⁰ Inappropriate study design – non comparativeSantillan 2011 ¹⁰¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate study design – non comparativeSokolowski 2018 ¹¹³ Inappropriate study design – non comparativeSokolowski 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Inappropriate study design – non comparativeSon 2010 ¹¹³ Inappropriate study design – non comparativeSon 2010 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁸ Systematic review: references checkedVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2008 ¹²¹ Paper not availab	Mutoh 2014 ⁹²	Inappropriate study design -citation only
Nibbelink 1975 ⁹⁷ Inappropriate study design – literature reviewNogueira 2007 ⁹⁸ Inappropriate study design – no comparison groupOtten 2008 ⁹⁹ Inappropriate study design – non comparativePala 2019 ¹⁰⁰ Inappropriate study design – non comparativePatel 2017 ¹⁰¹ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁶ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate intervention – prophylactic treatmentSanseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSehy 2010 ¹¹⁰ Inappropriate study design – non comparativeShankar 2011 ¹¹⁰ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design – non comparativeSutart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2001 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷¹ Inappropriate study design – non comparativeVan den Bergh 2009 ¹¹²⁰ Inappropriate study design – non comparativeVan den Bergh 2009 ¹¹²¹ Paper not availablevan den Bergh 2009 ¹¹²⁰ Inappropriate study design – interature review	Mutoh 2014 ⁹³	Inappropriate intervention – prophylactic treatment
Nogueira 2007 ¹⁸⁰ Inappropriate study design – no comparison groupOtten 2008 ¹⁹⁰ Inappropriate study design – non comparativePala 2019 ¹⁰⁰ Inappropriate study design – non comparativePatel 2017 ¹⁰¹ Inappropriate study design – non comparativeRobinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁶ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁷⁰ Inappropriate study design – non comparativeSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSanseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSanseethong 2018 ¹¹⁰⁹ Inappropriate study design – non comparativeSehy 2010 ¹¹⁰ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate study design – non comparativeSokolowski 2018 ¹¹³ Inappropriate study design – non comparativeSon 2010 ¹¹³ Inappropriate study design – non comparativeSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷⁰ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷¹ Inappropriate study design – non comparativeVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹²⁰ Inappropriate study design – literature reviewVan den Bergh 2009 ¹¹²⁰ Inappropriate study design – literature reviewVeldeman 2016	Narayan 2018 ⁹⁴	Inappropriate study design – no comparison group
Otten 2008**Inappropriate study design – literature reviewPala 2019***Inappropriate study design – non comparativePatel 2017***Inappropriate study design – non comparativeRobinson 1990***Systematic review: references checkedRomero 2009***Inappropriate study design – non comparativeRoy 2017***Inappropriate study design – non comparativeRoy 2017***Inappropriate study design – non comparativeRoy 2017***Inappropriate study design – non comparativeSadamasa 2014****Inappropriate study design – non comparativeSamseethong 2018****Inappropriate study design – non comparativeSanseethong 2018****Inappropriate study design – non comparativeSehy 2010*****Inappropriate study design – non comparativeSehy 2010*******Inappropriate study design – non comparativeShankar 2011***********************************	Nibbelink 1975 ⁹⁷	Inappropriate study design – literature review
Pala 2019100Inappropriate study design – non comparativePatel 2017101Inappropriate study design – non comparativeRobinson 1990104Systematic review: references checkedRomero 2009105Inappropriate study design – non comparativeRoy 2017106Inappropriate study design – non comparativeRoy 2017106Inappropriate study design – non comparativeSadamasa 2014107Inappropriate study design – non comparativeSamseethong 2018108Inappropriate intervention – prophylactic treatmentSantillan 2011109Inappropriate study design – non comparativeShankar 2011110Inappropriate study design – non comparativeShankar 2011111Inappropriate study design – non comparativeSokolowski 2018112Inappropriate study design – non comparativeSokolowski 2018112Inappropriate study design – non comparativeSokolowski 2018112Inappropriate study design – non comparativeSon 2010113Inappropriate study design – intraarterial infusions with or without angioplastySon 2010113Inappropriate study design – comparativeStuart 2018114Systematic review: references checkedSuarez 2011115Systematic review: references checkedTregiari 2009117Inappropriate study design – Interature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review:	Nogueira 2007 ⁹⁸	Inappropriate study design – no comparison group
Patel 2017101Inappropriate study design – non comparativeRobinson 1990104Systematic review: references checkedRomero 2009105Inappropriate study design – non comparativeRoy 2017106Inappropriate study design – Patients not matched and results not adjusted by ageSadamasa 2014107Inappropriate study design – non comparativeSamseethong 2018108Inappropriate study design – non comparativeSamseethong 2018109Inappropriate study design – non comparativeSantillan 2011109Inappropriate study design – non comparativeShankar 2010110Inappropriate study design – non comparativeShankar 2011111Inappropriate study design – non comparativeSokolowski 2018112Inappropriate study design – non comparativeSokolowski 2018112Inappropriate study design – non comparativeSon 2010113Inappropriate study design – citation onlyStuart 2018114Systematic review: references checkedSuarez 201115Systematic review: references checkedTreggiari 2009117Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – non comparativeVan den Bergh 2008121Paper not availablevan den Bergh 2009120Inappropriate review: references checkedvan den Bergh 2009120Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouw 2017126	Otten 200899	Inappropriate study design – literature review
Robinson 1990 ¹⁰⁴ Systematic review: references checkedRomero 2009 ¹⁰⁵ Inappropriate study design – non comparativeRoy 2017 ¹⁰⁸ Inappropriate study design – Patients not matched and results not adjusted by ageSadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁹ Inappropriate study design – non comparativeSahakar 2011 ¹¹⁰ Inappropriate study design – non comparativeShankar 2011 ¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design – non comparativeSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹²⁰ Inappropriate intervention – prophylacti treatmentVelat 2011 ¹²² Inappropriate study design – literature reviewVeldeman 2018 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouw 2017 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouw 2017 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatment	Pala 2019 ¹⁰⁰	Inappropriate study design – non comparative
Romero 2009105Inappropriate study design – non comparativeRoy 2017106Inappropriate study design - Patients not matched and results not adjusted by ageSadamasa 2014107Inappropriate study design – non comparativeSamseethong 2018108Inappropriate intervention – prophylactic treatmentSantillan 2011109Inappropriate study design – non comparativeSehy 2010110Inappropriate study design – non comparativeShankar 2011111Inappropriate study design – non comparativeSokolowski 2018112Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010113Inappropriate study design – non comparativeSuarez 2011115Systematic review: references checkedSuarez 2011115Systematic review: references checkedTreggiari 2009117Inappropriate study design – interature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009120Inappropriate review: references checkedvan den Bergh 2009120Inappropriate study design – literature reviewVelateman 2018123Systematic review: references checkedVelat 2011124Inappropriate study design – literature reviewVeldeman 2018123Systematic review: references checkedVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – literature reviewVergouwen 2011127Inappropriate study design – literature review	Patel 2017 ¹⁰¹	Inappropriate study design – non comparative
Roy 2017 ¹⁰⁶ Inappropriate study design - Patients not matched and results not adjusted by ageSadamasa 2014 ¹⁰⁷ Inappropriate study design - non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate intervention - prophylactic treatmentSantillan 2011 ¹⁰⁹ Inappropriate study design - non comparativeSehy 2010 ¹¹⁰ Inappropriate study design - non comparativeShankar 2011 ¹¹¹ Inappropriate study design - non comparativeSokolowski 2018 ¹¹² Inappropriate study design - non comparativeSokolowski 2018 ¹¹² Inappropriate comparison - intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁶ Inappropriate study design - non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design - non comparativeVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate study design - literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design - literature reviewVeldeman 2011 ¹²⁶ Inappropriate study design - non comparative / prophylactic treatmentVergouwen 2011 ¹²⁸ Inappropriate study design - non comparative / prophylactic treatmentVergouwen 2011 ¹²⁸ Inappropriate study design - non comparative / prophylactic treatment	Robinson 1990 ¹⁰⁴	Systematic review: references checked
Roy 2017 ¹⁰⁸ Inappropriate study design - Patients not matched and results not adjusted by ageSadamasa 2014 ¹⁰⁷ Inappropriate study design - non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate intervention - prophylactic treatmentSantillan 2011 ¹⁰⁹ Inappropriate study design - non comparativeSehy 2010 ¹¹⁰ Inappropriate study design - non comparativeShankar 2011 ¹¹¹ Inappropriate study design - non comparativeSokolowski 2018 ¹¹² Inappropriate study design - non comparativeSokolowski 2018 ¹¹² Inappropriate comparison - intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedTreggiari 2009 ¹¹⁷ Inappropriate study design - non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design - literature reviewvan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedVan den Bergh 2009 ¹²⁰ Inappropriate study design - literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVernatura 2018 ¹²⁴ Systematic review: references checkedVergouwen 2011 ¹²⁵ Inappropriate study design - literature reviewVeldeman 2018 ¹²⁴ Systematic review: references checkedVergouwen 2011 ¹²⁵ Inappropriate study design - non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design - non comparative / prophylactic treatment<	Romero 2009 ¹⁰⁵	Inappropriate study design – non comparative
Sadamasa 2014 ¹⁰⁷ Inappropriate study design – non comparativeSamseethong 2018 ¹⁰⁸ Inappropriate intervention – prophylactic treatmentSantillan 2011 ¹⁰⁹ Inappropriate study design – non comparativeSehy 2010 ¹¹⁰ Inappropriate study design – non comparativeShankar 2011 ¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design – citation onlyStuart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativevan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedvan den Bergh 2009 ¹¹⁰ Inappropriate intervention – prophylactic treatmentVelat 2011 ¹²² Inappropriate intervention – prophylactic treatmentVelat 2011 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatment	Roy 2017 ¹⁰⁶	Inappropriate study design - Patients not matched and results not
Samseethong 2018 ¹⁰⁸ Inappropriate intervention – prophylactic treatmentSantillan 2011 ¹⁰⁹ Inappropriate study design – non comparativeSehy 2010 ¹¹⁰ Inappropriate study design – non comparativeShankar 2011 ¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design - citation onlyStuart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedSuarez 2011 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – literature reviewvan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹²⁰ Inappropriate intervention – prophylactic treatmentVelat 2011 ¹²² Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – literature reviewVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatment	Sadamasa 2014 ¹⁰⁷	
Santillan 2011109Inappropriate study design – non comparativeSehy 2010110Inappropriate study design – non comparativeShankar 2011111Inappropriate study design – non comparativeSokolowski 2018112Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010113Inappropriate study design - citation onlyStuart 2018114Systematic review: references checkedSuarez 2011115Systematic review: references checkedSuarez 2011116Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – literature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatment	Samseethong 2018 ¹⁰⁸	
Sehy 2010 ¹¹⁰ Inappropriate study design – non comparativeShankar 2011 ¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design -citation onlyStuart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedTreggiari 2009 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – non comparativeVan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedvan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVenkatraman 2018 ¹²⁴ Systematic review: references checkedVergouwe 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁸ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatment	Ŭ	
Shankar 2011 ¹¹¹ Inappropriate study design – non comparativeSokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design - citation onlyStuart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedTrejada 2007 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – literature reviewvan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedvan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate study design – literature reviewVelat 2011 ¹²² Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁷ Inappropriate study design – non comparative / prophylactic treatment		
Sokolowski 2018 ¹¹² Inappropriate comparison – intraarterial infusions with or without angioplastySon 2010 ¹¹³ Inappropriate study design - citation onlyStuart 2018 ¹¹⁴ Systematic review: references checkedSuarez 2011 ¹¹⁵ Systematic review: references checkedTejada 2007 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – literature reviewvan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedvan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁷ Inappropriate study design – non comparative / prophylactic treatment	•	
Son 2010113Inappropriate study design -citation onlyStuart 2018114Systematic review: references checkedSuarez 2011115Systematic review: references checkedTejada 2007116Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – literature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009119Systematic review: references checkedvan den Bergh 2009119Systematic review: not review PICOvan den Bergh 2009120Inappropriate study design – literature reviewVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVergouwen 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011127Inappropriate study design – non comparative / prophylactic treatment		Inappropriate comparison – intraarterial infusions with or without
Stuart 2018114Systematic review: references checkedSuarez 2011115Systematic review: references checkedTejada 2007116Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – literature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009119Systematic review: references checkedvan den Bergh 2009119Systematic review: not review PICOvan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – non comparative / prophylactic treatment	Son 2010 ¹¹³	
Suarez 2011 ¹¹⁵ Systematic review: references checkedTejada 2007 ¹¹⁶ Inappropriate study design – non comparativeTreggiari 2009 ¹¹⁷ Inappropriate study design – literature reviewvan den Bergh 2008 ¹²¹ Paper not availablevan den Bergh 2009 ¹¹⁹ Systematic review: references checkedvan den Bergh 2009 ¹¹⁹ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate intervention – prophylactic treatmentVelat 2011 ¹²² Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – discussion articleWebb 2010 ¹²⁷ Inappropriate study design – no comparison group		
Tejada 2007116Inappropriate study design – non comparativeTreggiari 2009117Inappropriate study design – literature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009119Systematic review: references checkedvan den Bergh 2011118Systematic review: not review PICOvan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – non comparison group		-
Treggiari 2009117Inappropriate study design – literature reviewvan den Bergh 2008121Paper not availablevan den Bergh 2009119Systematic review: references checkedvan den Bergh 2011118Systematic review: not review PICOvan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		•
van den Bergh 2008121Paper not availablevan den Bergh 2009119Systematic review: references checkedvan den Bergh 2011118Systematic review: not review PICOvan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group	•	
van den Bergh 2009119Systematic review: references checkedvan den Bergh 2011118Systematic review: not review PICOvan den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group	00	
van den Bergh 2011 ¹¹⁸ Systematic review: not review PICOvan den Bergh 2009 ¹²⁰ Inappropriate intervention – prophylactic treatmentVelat 2011 ¹²² Inappropriate study design – literature reviewVeldeman 2016 ¹²³ Systematic review: references checkedVenkatraman 2018 ¹²⁴ Systematic review: references checkedVergouw 2017 ¹²⁵ Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011 ¹²⁶ Inappropriate study design – discussion articleWebb 2010 ¹²⁷ Inappropriate study design – no comparison group	•	•
van den Bergh 2009120Inappropriate intervention – prophylactic treatmentVelat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		-
Velat 2011122Inappropriate study design – literature reviewVeldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group	-	-
Veldeman 2016123Systematic review: references checkedVenkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		
Venkatraman 2018124Systematic review: references checkedVergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		
Vergouw 2017125Inappropriate study design – non comparative / prophylactic treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		-
treatmentVergouwen 2011126Inappropriate study design – discussion articleWebb 2010127Inappropriate study design – no comparison group		•
Webb 2010 ¹²⁷ Inappropriate study design – no comparison group	Vergouw 2017 ¹²⁵	
	Vergouwen 2011 ¹²⁶	Inappropriate study design – discussion article
Weyer 2006 ¹²⁸ Systematic review: references checked	Webb 2010 ¹²⁷	Inappropriate study design – no comparison group
	Weyer 2006 ¹²⁸	Systematic review: references checked

Study	Reason for exclusion
Williams 2020 ¹²⁹	Not review population – patients with SAH (not explicitly DCI)
Wong 2011 ¹³⁰	Systematic review: not review PICO
Yao 2017 ¹³¹	Systematic review: references checked
Zhang 2018 ¹³²	Inappropriate intervention – prophylactic treatment
Zhang 2013 ¹³³	Systematic review: references checked
Zhu 2001 ¹³⁴	Paper not available

I.21 Excluded health economic studies

- 2 Published health economic studies that met the inclusion criteria (relevant population,
- 3 comparators, economic study design, published 2003 or later and not from non-OECD
- 4 country or USA) but that were excluded following appraisal of applicability and
- 5 methodological quality are listed below. See the health economic protocol for more details.

6 Table 18: Studies excluded from the health economic review

Reference	Reason for exclusion
None.	